ketamine has been researched along with Pain, Chronic in 108 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Ketamine and its levogyre form, S-ketamine, have been used to treat chronic pain for many years without consensus about their therapeutic efficiency." | 9.41 | The place of S-ketamine in fibromyalgia treatment (ESKEFIB): study protocol for a prospective, single-center, double-blind, randomized, parallel-group, dose-escalation controlled trial. ( Dangoisse, M; Fils, JF; Gillain, A; Javorcikova, Z; Lechat, JP; Nikis, S; Van der Linden, P, 2021) |
| "In this article, we will review evidence for ketamine's role in chronic pain and mental health conditions, its current legal status and abuse potential, and the regulations related to its administration in stand-alone infusion clinics, as well as future considerations." | 9.41 | Ketamine for Chronic Pain and Mental Health: Regulations, Legalities, and the Growth of Infusion Clinics. ( Bloomfield, A; Chan, N; Fryml, L; Horace, R; Pyati, S, 2023) |
| "The aim of this clinical trial was to test if intraoperative low-dose ketamine without postoperative infusion would reduce PPSP development after breast cancer surgery." | 9.34 | Effects of Intraoperative Low-Dose Ketamine on Persistent Postsurgical Pain after Breast Cancer Surgery: A Prospective, Randomized, Controlled, Double-Blind Study. ( Baik, JS; Cho, AR; Kang, C; Kim, C; Kim, E; Kim, H; Kim, KH; Kwon, JY; Lee, EA; Lee, HJ, 2020) |
| " diclofenac monotherapy in reducing symptoms of mild to moderate depression among patients with chronic pain." | 9.22 | Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: A double-blind, randomized, controlled trial. ( Afarideh, M; Agah, E; Akhondzadeh, S; Arbabi, M; Ghajar, A; Jafarinia, M; Noorbala, AA; Saravi, MA; Tafakhori, A, 2016) |
| "CYP2B6 genotypes were identified in 49 chronic pain patients who received 24 h continuous subcutaneous infusions of ketamine." | 9.20 | CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects. ( Coller, JK; Currow, DC; Franco, M; Hardy, JR; Hutchinson, MR; Jackson, KA; Li, Y; Poon, P; Slon, B; Somogyi, AA; William, L, 2015) |
| "Adding epidural or IV racemic ketamine to TEA after thoracotomy did not lead to any reduction in PPP or allodynia." | 9.19 | Perioperative epidural or intravenous ketamine does not improve the effectiveness of thoracic epidural analgesia for acute and chronic pain after thoracotomy. ( Gomar, C; Rios, J; Tena, B, 2014) |
| "The observed treatment effects in chronic pain patients suggest a role for CPM engagement in analgesic efficacy of ketamine, morphine, and placebo treatment." | 9.17 | Influence of ketamine and morphine on descending pain modulation in chronic pain patients: a randomized placebo-controlled cross-over proof-of-concept study. ( Aarts, L; Dahan, A; Niesters, M; Sarton, E, 2013) |
| "To assess whether oral ketamine is safe at higher dosages for sedating children and whether it may be an option for the control of chronic pain in children." | 9.17 | Oral ketamine for children with chronic pain: a pilot phase 1 study. ( Adams, HR; Bredlau, AL; Dolan, JG; Dworkin, RH; Fisher, SG; Korones, DN; McDermott, MP; Venuto, C, 2013) |
| "Ketamine is used as an analgesic for treatment of acute and chronic pain." | 9.16 | The dose-dependent effect of S(+)-ketamine on cardiac output in healthy volunteers and complex regional pain syndrome type 1 chronic pain patients. ( Aarts, L; Bauer, M; Dahan, A; Mooren, R; Niesters, M; Noppers, I; Olofsen, E; Sarton, E; Sigtermans, M, 2012) |
| "IV ketamine is widely used to treat patients with chronic pain, yet the long-term impact remains uncertain." | 9.01 | Ketamine Infusions for Chronic Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials. ( Bhatia, A; Cohen, SP; Orhurhu, MS; Orhurhu, V, 2019) |
| "Over the past 2 decades, the use of intravenous ketamine infusions as a treatment for chronic pain has increased dramatically, with wide variation in patient selection, dosing, and monitoring." | 8.98 | Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. ( Bhatia, A; Buvanendran, A; Cohen, SP; Davis, FN; Hooten, WM; Hurley, RW; Lubenow, TR; Narouze, S; Ritchie, EC; Schwenk, ES; Viscusi, ER; Wasan, AD, 2018) |
| "Ketamine is frequently used in the management of refractory chronic pain." | 8.98 | [Ketamine and chronic pain: A narrative review of its efficacy and its adverse events]. ( Micallef, J; Morel, V; Pickering, G, 2018) |
| "The anaesthetic ketamine is used to treat various chronic pain syndromes, especially those that have a neuropathic component." | 8.90 | Ketamine for chronic pain: risks and benefits. ( Dahan, A; Martini, C; Niesters, M, 2014) |
| "Ketamine is now frequently used in the management of chronic pain refractory to conventional treatments." | 8.31 | [Ketamine in chronic pain]. ( Pickering, G, 2023) |
| " Neuropathic pain represents the first indication to use ketamine, followed, with a good to moderate utility, by other situations (fibromyalgia, complex regional pain syndrome, central neuropathic pain, peripheral neuropathic pain, nociceptive pain, sensitization, opioid withdrawal, palliative care, depression)." | 8.12 | Ketamine in chronic pain: A Delphi survey. ( Amodéo, JM; André, G; Barmaki, M; Collard, O; Colomb, C; Créac'h, C; de Chazeron, I; de Montgazon, G; Deleens, R; Delorme, C; Dixneuf, V; Dy, L; Gaillard, J; Gov, C; Kieffer, X; Lanteri-Minet, M; Le Borgne, JM; Le Caër, F; Maamar, F; Maindet, C; Marcaillou, F; Morel, V; Pickering, G; Plantevin, F; Pluchon, YM; Riant, T; Rioult, B; Rostaing, S; Salvat, E; Sep Hieng, V; Sorel, M; Vergne-Salle, P; Voute, M, 2022) |
| "Ketamine is an anesthetic drug which is now used to treat chronic pain conditions and psychiatric disorders, especially depression." | 8.12 | Ketamine as a therapeutic agent for depression and pain: mechanisms and evidence. ( Haroutounian, S; Lenze, EJ; Palanca, BJA; Subramanian, S, 2022) |
| " Thirty-one clinics used ketamine for chronic pain treatment." | 8.12 | Ketamine therapy for chronic pain in The Netherlands: a nationwide survey. ( Bharwani, KD; Dirckx, M; Huygen, FJPM; Mangnus, TJP; Stronks, DL, 2022) |
| "Ketamine is often used in pain clinics for refractory chronic pain, but its long-term efficacy is poorly reported." | 8.12 | Ketamine for refractory chronic pain: a 1-year follow-up study. ( Corriger, A; Lambert, C; Pereira, B; Pickering, G; Voute, M, 2022) |
| "Ketamine has been used to treat chronic pain; however, it is still unknown as to what types of chronic pain is ketamine effective against." | 7.91 | Resting-state brain functional connectivity in patients with chronic pain who responded to subanesthetic-dose ketamine. ( Izuta, S; Kan, S; Mizobuchi, S; Motoyama, Y; Obata, N; Oshiro, Y; Sato, H; Takao, Y, 2019) |
| "Ketamine is a standard anaesthetic drug that has been studied as a possible treatment for acute suicidal ideation." | 7.85 | Use of ketamine for acute suicidal ideation in a patient with chronic pain on prescribed cannabinoids. ( Bigman, D; Bobrin, B; Kunaparaju, S, 2017) |
| "Before updating the French guidelines on postoperative pain treatment in 2015, the Pain Committee of the French Society of Anaesthesiology and Intensive Care (SFAR) conducted a survey on the medical use of ketamine in France." | 7.81 | Ketamine for pain management in France, an observational survey. ( Beloeil, H; Derivaux, B; Martinez, V, 2015) |
| "Over a 15-month period, 63 children and adolescents (median age 15, interquartile range 12-17 years) with chronic pain received 277 ketamine infusions." | 7.81 | Subanesthetic ketamine infusions for the treatment of children and adolescents with chronic pain: a longitudinal study. ( Finkel, JC; Lippold, C; Muller, EA; Nouraie, M; Quezado, ZM; Sheehy, KA, 2015) |
| "In this RCT, the primary objective is to demonstrate that an intermittent esketamine dosing regimen is non-inferior to a continuous esketamine dosing regimen at 3 months follow-up." | 7.30 | Intermittent versus continuous esketamine infusions for long-term pain modulation in complex regional pain syndrome: protocol of a randomized controlled non-inferiority study (KetCRPS-2). ( Baart, SJ; Bharwani, KD; de Vos, CC; Dik, WA; Dirckx, M; Huygen, FJPM; Mangnus, TJP; Redekop, K; Siepman, TAM, 2023) |
| " The results indicate that low-dose ketamine infusions produce subtle changes in QST phenotypes that are modified by the chronic use of opioids." | 6.84 | Chronic Opioid Therapy Modifies QST Changes After Ketamine Infusion in Chronic Pain Patients. ( Ahmed, S; Chen, L; Doshi, T; Maher, DP; Malarick, C; Mao, J; Stabach, K; Zhang, Y, 2017) |
| "Our primary objective was test the hypothesis that oral methadone combined with oral ketamine is more effective than oral methadone or ketamine alone in reducing neuropathic pain." | 6.84 | Management of Neuropathic Chronic Pain with Methadone Combined with Ketamine: A Randomized, Double Blind, Active-Controlled Clinical Trial. ( Caumo, W; Dalmolin, GD; Ferreira, J; Godoy, MC; Menezes, MS; Rigo, FK; Rossato, MF; Silva, MA; Trevisan, G, 2017) |
| "Ketamine is an adjuvant demonstrating analgesic and opioid-sparing effects." | 6.78 | Ketamine decreases postoperative pain scores in patients taking opioids for chronic pain: results of a prospective, randomized, double-blind study. ( Barreveld, AM; Correll, DJ; Liu, X; Max, B; McGowan, JA; Nedeljkovic, SS; Shovel, L; Wasan, AD, 2013) |
| "Ketamine has unique pharmacologic properties that may prevent the development of pain as well as reduce chronic pain." | 6.58 | Emerging Trends in Pain Medication Management: Back to the Future: A Focus on Ketamine. ( Atkinson, TJ; Bryant, C; Crumb, MW, 2018) |
| "Only the analysis of postoperative pain at rest after 1 month resulted in a marginally significant reduction of chronic postoperative pain using ketamine in the perioperative setting." | 6.52 | Intra- and postoperative intravenous ketamine does not prevent chronic pain: A systematic review and meta-analysis. ( Bandschapp, O; Girard, T; Klatt, E; Ruppen, W; Zumbrunn, T, 2015) |
| "What questions did we seek to answer? Chronic pain is a common problem with limited effective treatments." | 5.91 | Therapeutic effects of 7- to 14-day subanesthetic ketamine infusions for chronic pain on standardized psychiatric measures. ( Marzoughi, S; Ong, M; Ripsman, D, 2023) |
| "Ketamine is a pharmacological agent that was developed in the 1960s." | 5.72 | The effects of a multiday (10-14 days) subanesthetic dose IV ketamine infusion in the treatment of refractory chronic pain. ( Chebini, A; Fedoroff, I; Guh, D; Marzoughi, S; Ong, M; Randhawa, J; Wiseman, S, 2022) |
| "Co-existing chronic pain and depression pose a serious socio-economic burden and result in disability affecting millions of individuals, which urges the development of treatment strategies targeting this comorbidity." | 5.56 | Ketamine induces rapid and sustained antidepressant-like effects in chronic pain induced depression: Role of MAPK signaling pathway. ( Ayazgök, B; Becker, LJ; Humo, M; Rantamäki, T; Waltisperger, E; Yalcin, I, 2020) |
| "Ketamine was effective in 24 patients (44%, mean pain reduction 67 ± 17%), partially effective in 20% (mean pain reduction 30 ± 11%), with a mean opioid sparing of 63 ± 32%, and failure in 22%." | 5.42 | Efficacy and safety of oral ketamine for the relief of intractable chronic pain: A retrospective 5-year study of 51 patients. ( Bellanger, A; Bourgeois, P; Coutaux, A; Magneux, C; Marchetti, F; Mion, G, 2015) |
| "In this article, we will review evidence for ketamine's role in chronic pain and mental health conditions, its current legal status and abuse potential, and the regulations related to its administration in stand-alone infusion clinics, as well as future considerations." | 5.41 | Ketamine for Chronic Pain and Mental Health: Regulations, Legalities, and the Growth of Infusion Clinics. ( Bloomfield, A; Chan, N; Fryml, L; Horace, R; Pyati, S, 2023) |
| " Ketamine and its levogyre form, S-ketamine, have been used to treat chronic pain for many years without consensus about their therapeutic efficiency." | 5.41 | The place of S-ketamine in fibromyalgia treatment (ESKEFIB): study protocol for a prospective, single-center, double-blind, randomized, parallel-group, dose-escalation controlled trial. ( Dangoisse, M; Fils, JF; Gillain, A; Javorcikova, Z; Lechat, JP; Nikis, S; Van der Linden, P, 2021) |
| "The aim of this clinical trial was to test if intraoperative low-dose ketamine without postoperative infusion would reduce PPSP development after breast cancer surgery." | 5.34 | Effects of Intraoperative Low-Dose Ketamine on Persistent Postsurgical Pain after Breast Cancer Surgery: A Prospective, Randomized, Controlled, Double-Blind Study. ( Baik, JS; Cho, AR; Kang, C; Kim, C; Kim, E; Kim, H; Kim, KH; Kwon, JY; Lee, EA; Lee, HJ, 2020) |
| " Adults without chronic pain and undergoing any elective cardiac surgery patients via sternotomy were randomly assigned to receive either usual care, pregabalin (150 mg preoperatively and twice daily for 14 postoperative days) alone, or pregabalin in combination with a 48-h postoperative infusion of intravenous ketamine at 0." | 5.30 | Prolonged Perioperative Use of Pregabalin and Ketamine to Prevent Persistent Pain after Cardiac Surgery. ( Anwar, S; Cooper, J; Langford, R; Rahman, J; Sharma, C, 2019) |
| " diclofenac monotherapy in reducing symptoms of mild to moderate depression among patients with chronic pain." | 5.22 | Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: A double-blind, randomized, controlled trial. ( Afarideh, M; Agah, E; Akhondzadeh, S; Arbabi, M; Ghajar, A; Jafarinia, M; Noorbala, AA; Saravi, MA; Tafakhori, A, 2016) |
| "CYP2B6 genotypes were identified in 49 chronic pain patients who received 24 h continuous subcutaneous infusions of ketamine." | 5.20 | CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects. ( Coller, JK; Currow, DC; Franco, M; Hardy, JR; Hutchinson, MR; Jackson, KA; Li, Y; Poon, P; Slon, B; Somogyi, AA; William, L, 2015) |
| "Adding epidural or IV racemic ketamine to TEA after thoracotomy did not lead to any reduction in PPP or allodynia." | 5.19 | Perioperative epidural or intravenous ketamine does not improve the effectiveness of thoracic epidural analgesia for acute and chronic pain after thoracotomy. ( Gomar, C; Rios, J; Tena, B, 2014) |
| "To assess whether oral ketamine is safe at higher dosages for sedating children and whether it may be an option for the control of chronic pain in children." | 5.17 | Oral ketamine for children with chronic pain: a pilot phase 1 study. ( Adams, HR; Bredlau, AL; Dolan, JG; Dworkin, RH; Fisher, SG; Korones, DN; McDermott, MP; Venuto, C, 2013) |
| "The observed treatment effects in chronic pain patients suggest a role for CPM engagement in analgesic efficacy of ketamine, morphine, and placebo treatment." | 5.17 | Influence of ketamine and morphine on descending pain modulation in chronic pain patients: a randomized placebo-controlled cross-over proof-of-concept study. ( Aarts, L; Dahan, A; Niesters, M; Sarton, E, 2013) |
| "Ketamine is used as an analgesic for treatment of acute and chronic pain." | 5.16 | The dose-dependent effect of S(+)-ketamine on cardiac output in healthy volunteers and complex regional pain syndrome type 1 chronic pain patients. ( Aarts, L; Bauer, M; Dahan, A; Mooren, R; Niesters, M; Noppers, I; Olofsen, E; Sarton, E; Sigtermans, M, 2012) |
| " Emphasis will be on the old-new drugs, ketamine and magnesium, and their combination as a novel approach for treating chronic pain." | 5.12 | Interactions between Ketamine and Magnesium for the Treatment of Pain: Current State of the Art. ( Divac, N; Medić, B; Prostran, M; Srebro, D; Stojanović, R; Vučković, S; Vujović, A; Vujović, KS, 2021) |
| "IV ketamine is widely used to treat patients with chronic pain, yet the long-term impact remains uncertain." | 5.01 | Ketamine Infusions for Chronic Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials. ( Bhatia, A; Cohen, SP; Orhurhu, MS; Orhurhu, V, 2019) |
| "In study IV we hypothesized that intraoperative ketamine would reduce postoperative opioid consumption and persistent pain after spinal fusion surgery in chronic pain patients with opioid dependency." | 4.98 | Adjuvant analgesics for spine surgery. ( Nielsen, RV, 2018) |
| "Ketamine is frequently used in the management of refractory chronic pain." | 4.98 | [Ketamine and chronic pain: A narrative review of its efficacy and its adverse events]. ( Micallef, J; Morel, V; Pickering, G, 2018) |
| "Over the past 2 decades, the use of intravenous ketamine infusions as a treatment for chronic pain has increased dramatically, with wide variation in patient selection, dosing, and monitoring." | 4.98 | Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. ( Bhatia, A; Buvanendran, A; Cohen, SP; Davis, FN; Hooten, WM; Hurley, RW; Lubenow, TR; Narouze, S; Ritchie, EC; Schwenk, ES; Viscusi, ER; Wasan, AD, 2018) |
| "Ketamine has been suggested to be efficient in relieving chronic pain." | 4.98 | Ketamine for chronic non-cancer pain: A meta-analysis and trial sequential analysis of randomized controlled trials. ( Bellon, M; Brasher, C; Dahmani, S; Horlin, AL; Julien-Marsollier, F; Michelet, D; Pontone, S; Vacher, T, 2018) |
| "Searches in PubMed with the terms 'oral ketamine', 'depression', 'chronic pain', 'neuropathic pain', 'intravenous ketamine', 'intranasal ketamine' and 'subcutaneous ketamine' yielded 88 articles." | 4.93 | Oral ketamine for the treatment of pain and treatment-resistant depression†. ( aan het Rot, M; Balukova, SM; Chaves, TV; Kortekaas, R; Schoevers, RA, 2016) |
| "The anaesthetic ketamine is used to treat various chronic pain syndromes, especially those that have a neuropathic component." | 4.90 | Ketamine for chronic pain: risks and benefits. ( Dahan, A; Martini, C; Niesters, M, 2014) |
| "Ketamine is now frequently used in the management of chronic pain refractory to conventional treatments." | 4.31 | [Ketamine in chronic pain]. ( Pickering, G, 2023) |
| "What is this study about? This study examined data of patients with chronic pain who received an infusion at our hospital with two drugs, lidocaine and ketamine, in an effort to reduce pain." | 4.31 | Simultaneous application of lidocaine and ketamine during ambulatory infusion therapy: a retrospective analysis. ( Ruppen, W; Schneider, T; Striebel, J, 2023) |
| "Repeated ketamine administration is common in treatment-refractory chronic pain, but ketamine analgesic and antidepressant effects are poorly understood in patients with chronic pain with depression symptoms." | 4.31 | Assessment of Initial Depressive State and Pain Relief With Ketamine in Patients With Chronic Refractory Pain. ( Lambert, C; Pereira, B; Pickering, G; Voute, M, 2023) |
| "Ketamine is often used in pain clinics for refractory chronic pain, but its long-term efficacy is poorly reported." | 4.12 | Ketamine for refractory chronic pain: a 1-year follow-up study. ( Corriger, A; Lambert, C; Pereira, B; Pickering, G; Voute, M, 2022) |
| " Thirty-one clinics used ketamine for chronic pain treatment." | 4.12 | Ketamine therapy for chronic pain in The Netherlands: a nationwide survey. ( Bharwani, KD; Dirckx, M; Huygen, FJPM; Mangnus, TJP; Stronks, DL, 2022) |
| " Neuropathic pain represents the first indication to use ketamine, followed, with a good to moderate utility, by other situations (fibromyalgia, complex regional pain syndrome, central neuropathic pain, peripheral neuropathic pain, nociceptive pain, sensitization, opioid withdrawal, palliative care, depression)." | 4.12 | Ketamine in chronic pain: A Delphi survey. ( Amodéo, JM; André, G; Barmaki, M; Collard, O; Colomb, C; Créac'h, C; de Chazeron, I; de Montgazon, G; Deleens, R; Delorme, C; Dixneuf, V; Dy, L; Gaillard, J; Gov, C; Kieffer, X; Lanteri-Minet, M; Le Borgne, JM; Le Caër, F; Maamar, F; Maindet, C; Marcaillou, F; Morel, V; Pickering, G; Plantevin, F; Pluchon, YM; Riant, T; Rioult, B; Rostaing, S; Salvat, E; Sep Hieng, V; Sorel, M; Vergne-Salle, P; Voute, M, 2022) |
| "Ketamine is an anesthetic drug which is now used to treat chronic pain conditions and psychiatric disorders, especially depression." | 4.12 | Ketamine as a therapeutic agent for depression and pain: mechanisms and evidence. ( Haroutounian, S; Lenze, EJ; Palanca, BJA; Subramanian, S, 2022) |
| "Ketamine use has increased recently for the management of acute and chronic pain." | 4.12 | Risk Factors for the Development of Neuropsychiatric Adverse Effects in Ketamine-Treated Pain. ( Quirk, K; Smith, MA, 2022) |
| " Sublingual ketamine has been shown to be efficacious for use in chronic pain." | 4.12 | Long-term safety and efficacy of sublingual ketamine troches/lozenges in chronic non-malignant pain management. ( Aggarwal, A; Gibson, SB; Maudlin, B, 2022) |
| "Emerging off-label medical uses of ketamine for the treatment of persistent conditions such as depression and chronic pain often require repeated administration." | 4.02 | Repeated or Continuous Medically Supervised Ketamine Administration Associated with Hepatobiliary Adverse Events: A Retrospective Case Series. ( Avigan, M; Chai, G; Cotter, S; Foster, D; Gada, N; Gill, R; Jones, SC; Mundkur, M; Wong, J, 2021) |
| "This study aimed to develop a method that objectively measures the clinical benefits of ketamine infusions to treat complex regional pain syndrome (CRPS), thus making it possible, for the first time, to determine the optimal dosing of ketamine and duration of treatment to treat CRPS." | 3.96 | Optimizing the Treatment of CRPS With Ketamine. ( Alexander, J; Bavry, E; Kirkpatrick, AF; Qiu, P; Saghafi, A; Schwartzman, R; Yang, K, 2020) |
| " Osteoarthritis was induced in male adult control Wistar rats without any interventions and in Wisket rats after juvenile social isolation and ketamine treatment." | 3.96 | Distinct changes in chronic pain sensitivity and oxytocin receptor expression in a new rat model (Wisket) of schizophrenia. ( Banki, L; Büki, A; Horvath, G; Jancsó, G; Kekesi, G; Kis, G; Somogyvári, F; Tuboly, G; Varga, E; Vécsei, L, 2020) |
| "Ketamine has been used to treat chronic pain; however, it is still unknown as to what types of chronic pain is ketamine effective against." | 3.91 | Resting-state brain functional connectivity in patients with chronic pain who responded to subanesthetic-dose ketamine. ( Izuta, S; Kan, S; Mizobuchi, S; Motoyama, Y; Obata, N; Oshiro, Y; Sato, H; Takao, Y, 2019) |
| "Ketamine is a standard anaesthetic drug that has been studied as a possible treatment for acute suicidal ideation." | 3.85 | Use of ketamine for acute suicidal ideation in a patient with chronic pain on prescribed cannabinoids. ( Bigman, D; Bobrin, B; Kunaparaju, S, 2017) |
| "A 41-year-old woman with chronic pelvic pain and previous ketamine exposure developed a widespread urticarial rash and mild perioral edema following the initiation of a ketamine infusion." | 3.83 | Immunoglobulin E-Mediated Hypersensitivity Reaction to Ketamine. ( Jones, K; Nicholls, K; Ozcan, J, 2016) |
| "Over a 15-month period, 63 children and adolescents (median age 15, interquartile range 12-17 years) with chronic pain received 277 ketamine infusions." | 3.81 | Subanesthetic ketamine infusions for the treatment of children and adolescents with chronic pain: a longitudinal study. ( Finkel, JC; Lippold, C; Muller, EA; Nouraie, M; Quezado, ZM; Sheehy, KA, 2015) |
| "Before updating the French guidelines on postoperative pain treatment in 2015, the Pain Committee of the French Society of Anaesthesiology and Intensive Care (SFAR) conducted a survey on the medical use of ketamine in France." | 3.81 | Ketamine for pain management in France, an observational survey. ( Beloeil, H; Derivaux, B; Martinez, V, 2015) |
| "Given that the analgesic effect of S-ketamine is due to both S-ketamine and norketamine, relatively small oral doses of S-ketamine can be assumed to be a feasible alternative to repeated intravenous dosing, for example in the setting of chronic pain." | 3.81 | Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing. ( Backman, JT; Fanta, S; Kalso, E; Kinnunen, M, 2015) |
| "To report our early results of augmentation enterocystoplasty (AE) for severe bladder pain associated with chronic ketamine cystitis (KC)." | 3.80 | Augmentation enterocystoplasty is effective in relieving refractory ketamine-related bladder pain. ( Chung, SD; Kuo, HC; Wang, CC, 2014) |
| "In this RCT, the primary objective is to demonstrate that an intermittent esketamine dosing regimen is non-inferior to a continuous esketamine dosing regimen at 3 months follow-up." | 3.30 | Intermittent versus continuous esketamine infusions for long-term pain modulation in complex regional pain syndrome: protocol of a randomized controlled non-inferiority study (KetCRPS-2). ( Baart, SJ; Bharwani, KD; de Vos, CC; Dik, WA; Dirckx, M; Huygen, FJPM; Mangnus, TJP; Redekop, K; Siepman, TAM, 2023) |
| "Chronic postsurgical pain (CPSP) has become a common complication during the perioperative period." | 3.01 | Effects of Ketamine on Chronic Postsurgical Pain in Patients Undergoing Surgery: A Systematic Review and Meta-analysis. ( Cui, Y; Fan, J; Fu, Y; Han, R; Sun, W; Wang, J; Wang, L; Wu, Y; Yu, Y; Zhou, Y, 2023) |
| " The results indicate that low-dose ketamine infusions produce subtle changes in QST phenotypes that are modified by the chronic use of opioids." | 2.84 | Chronic Opioid Therapy Modifies QST Changes After Ketamine Infusion in Chronic Pain Patients. ( Ahmed, S; Chen, L; Doshi, T; Maher, DP; Malarick, C; Mao, J; Stabach, K; Zhang, Y, 2017) |
| "Our primary objective was test the hypothesis that oral methadone combined with oral ketamine is more effective than oral methadone or ketamine alone in reducing neuropathic pain." | 2.84 | Management of Neuropathic Chronic Pain with Methadone Combined with Ketamine: A Randomized, Double Blind, Active-Controlled Clinical Trial. ( Caumo, W; Dalmolin, GD; Ferreira, J; Godoy, MC; Menezes, MS; Rigo, FK; Rossato, MF; Silva, MA; Trevisan, G, 2017) |
| "Ketamine and nefopam has been documented to decrease pain intensity and improve rehabilitation after total knee arthroplasty (TKA)." | 2.79 | Pain and recovery after total knee arthroplasty: a 12-month follow-up after a prospective randomized study evaluating Nefopam and Ketamine for early rehabilitation. ( Aveline, C; Bonnet, F; Cognet, F; Gautier, JF; Hetet, HL; Roux, AL; Vautier, P, 2014) |
| "Ketamine is an adjuvant demonstrating analgesic and opioid-sparing effects." | 2.78 | Ketamine decreases postoperative pain scores in patients taking opioids for chronic pain: results of a prospective, randomized, double-blind study. ( Barreveld, AM; Correll, DJ; Liu, X; Max, B; McGowan, JA; Nedeljkovic, SS; Shovel, L; Wasan, AD, 2013) |
| "Ketamine is an effective and safe multimodal analgesic in patients undergoing breast surgery, administered both intravenously and when added to bupivacaine in paravertebral blocks." | 2.72 | The Effect of Ketamine on Acute and Chronic Wound Pain in Patients Undergoing Breast Surgery: A Meta-Analysis and Systematic Review. ( Bi, Y; Liu, B; Ma, J; Ye, Y; Zhang, X; Zhu, Y, 2021) |
| " Our aim was to develop a comprehensive Ketamine Side Effect Tool (KSET) to capture acute and longer-term side effects associated with repeated ketamine treatments." | 2.66 | Development of the Ketamine Side Effect Tool (KSET). ( Bayes, AJ; Dong, V; Fam, J; Fraguas, R; Gálvez, V; Glue, P; Loo, CK; Martin, D; McLoughlin, DM; McShane, R; Murrough, JW; Riva-Posse, P; Schoevers, R; Short, B; Vulovic, V; Zarate, CA, 2020) |
| "Chronic postsurgical pain (CPSP) is an important and well recognized cause of much long-term suffering, which in some cases may be preventable and affects many people living with cancer." | 2.58 | Chronic postsurgical pain and cancer: the catch of surviving the unsurvivable. ( Bhaskar, A; Humble, SR; Jayaweera, A; Varela, N, 2018) |
| "Ketamine has unique pharmacologic properties that may prevent the development of pain as well as reduce chronic pain." | 2.58 | Emerging Trends in Pain Medication Management: Back to the Future: A Focus on Ketamine. ( Atkinson, TJ; Bryant, C; Crumb, MW, 2018) |
| "Chronic postoperative pain is common." | 2.53 | Preventing chronic postoperative pain. ( Reddi, D, 2016) |
| "Only the analysis of postoperative pain at rest after 1 month resulted in a marginally significant reduction of chronic postoperative pain using ketamine in the perioperative setting." | 2.52 | Intra- and postoperative intravenous ketamine does not prevent chronic pain: A systematic review and meta-analysis. ( Bandschapp, O; Girard, T; Klatt, E; Ruppen, W; Zumbrunn, T, 2015) |
| "Quality pain management for cancer survivors is complicated by the fact that cancer-related pain can be due to the tumor, surgery, radiation, and/or chemotherapy." | 2.50 | Understanding the cancer pain experience. ( Schreiber, JA, 2014) |
| " Highly variable timing and dosing of ketamine in these studies suggest that no unifying effective regimen has emerged." | 2.50 | A systematic review and meta-analysis of ketamine for the prevention of persistent post-surgical pain. ( Haroutounian, S; McNicol, ED; Schumann, R, 2014) |
| "Recent awareness that chronic pain may occur after childbirth has prompted clinicians and researchers to investigate this topic." | 2.49 | Chronic pain after childbirth. ( Bollag, L; Landau, R; Ortner, C, 2013) |
| "Urological toxicity, hepatotoxicity and cognitive deficits are all reported as adverse effects of the recreational use of ketamine." | 2.48 | Ketamine for chronic noncancer pain: concerns regarding toxicity. ( Bell, RF, 2012) |
| "What questions did we seek to answer? Chronic pain is a common problem with limited effective treatments." | 1.91 | Therapeutic effects of 7- to 14-day subanesthetic ketamine infusions for chronic pain on standardized psychiatric measures. ( Marzoughi, S; Ong, M; Ripsman, D, 2023) |
| "Currently, the treatment of SCD acute pain only targets its symptoms, rather than underlying mechanisms, and is directed by expert and consensus guidelines." | 1.72 | Subanesthetic ketamine: the way forward for pain management in sickle cell disease patients? ( Carullo, V; Nobrega, R; Quezado, ZMN; Thein, SL, 2022) |
| "Ketamine is a pharmacological agent that was developed in the 1960s." | 1.72 | The effects of a multiday (10-14 days) subanesthetic dose IV ketamine infusion in the treatment of refractory chronic pain. ( Chebini, A; Fedoroff, I; Guh, D; Marzoughi, S; Ong, M; Randhawa, J; Wiseman, S, 2022) |
| "Using a mouse model, we found that neuropathic pain caused an increase in ACC in vivo activity, as measured by the indirect activity marker c-Fos and juxtacellular electrophysiological recordings." | 1.62 | Increased burst coding in deep layers of the ventral anterior cingulate cortex during neuropathic pain. ( Kasanetz, F; Nevian, T, 2021) |
| "Co-existing chronic pain and depression pose a serious socio-economic burden and result in disability affecting millions of individuals, which urges the development of treatment strategies targeting this comorbidity." | 1.56 | Ketamine induces rapid and sustained antidepressant-like effects in chronic pain induced depression: Role of MAPK signaling pathway. ( Ayazgök, B; Becker, LJ; Humo, M; Rantamäki, T; Waltisperger, E; Yalcin, I, 2020) |
| "Pharmacological management of neuropathic pain should be based on a stepwise intervention strategy, as combinations of medications are the most effective approach." | 1.51 | Neuropathic Pain in Pediatric Oncology: A Clinical Decision Algorithm. ( Anghelescu, DL; Tesney, JM, 2019) |
| "Chronic pain is known to induce an amplified aversive reaction to peripheral nociceptive inputs." | 1.48 | Ketamine reduces aversion in rodent pain models by suppressing hyperactivity of the anterior cingulate cortex. ( Chen, Z; Dale, J; Hu, S; Huang, D; Liu, K; Martinez, E; Wang, J; Yang, G; Zhang, E; Zhang, Q; Zhou, H, 2018) |
| " Continuous intravenous ketamine infusions were the most common route of administration (65%); however, wide variability in dosing and length of therapy was reported." | 1.48 | Current Ketamine Practice: Results of the 2016 American Society of Pain Management Nursing Survey on Ketamine. ( Jungquist, CR; Klaess, CC, 2018) |
| "Cyclobenzaprine specimens were equally likely to be positive whether the dose was oral or topical, although mean levels after topical dosing were approximately 13-21% those after oral dosing." | 1.46 | Urinary Concentrations of Topically Administered Pain Medications. ( Bell, P; Glinn, MA; Harvey, A; Lickteig, AJ; Rappold, B; Recer, S; Salske, M; Stensland, J; Weber, L, 2017) |
| "Ketamine was effective in 24 patients (44%, mean pain reduction 67 ± 17%), partially effective in 20% (mean pain reduction 30 ± 11%), with a mean opioid sparing of 63 ± 32%, and failure in 22%." | 1.42 | Efficacy and safety of oral ketamine for the relief of intractable chronic pain: A retrospective 5-year study of 51 patients. ( Bellanger, A; Bourgeois, P; Coutaux, A; Magneux, C; Marchetti, F; Mion, G, 2015) |
| "Persistent postsurgical pain has been defined by the International Association for the Study of Pain as clinical discomfort that lasts more than two months after surgery." | 1.42 | Potential strategies for preventing chronic postoperative pain: a practical approach: Continuing Professional Development. ( Brulotte, V; Julien, M; Richebé, P, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 70 (64.81) | 24.3611 |
| 2020's | 38 (35.19) | 2.80 |
| Authors | Studies |
|---|---|
| Chebini, A | 1 |
| Marzoughi, S | 2 |
| Randhawa, J | 1 |
| Guh, D | 1 |
| Wiseman, S | 1 |
| Fedoroff, I | 1 |
| Ong, M | 2 |
| Cotter, S | 1 |
| Wong, J | 1 |
| Gada, N | 1 |
| Gill, R | 1 |
| Jones, SC | 1 |
| Chai, G | 1 |
| Foster, D | 1 |
| Avigan, M | 1 |
| Mundkur, M | 1 |
| Javorcikova, Z | 1 |
| Dangoisse, M | 1 |
| Nikis, S | 1 |
| Lechat, JP | 1 |
| Gillain, A | 1 |
| Fils, JF | 1 |
| Van der Linden, P | 1 |
| Kasanetz, F | 1 |
| Nevian, T | 1 |
| McGregor, RH | 1 |
| Warner, FM | 1 |
| Linde, LD | 1 |
| Cragg, JJ | 1 |
| Osborn, JA | 1 |
| Varshney, VP | 1 |
| Schwarz, SKW | 1 |
| Kramer, JLK | 1 |
| Voute, M | 3 |
| Riant, T | 1 |
| Amodéo, JM | 1 |
| André, G | 1 |
| Barmaki, M | 1 |
| Collard, O | 1 |
| Colomb, C | 1 |
| Créac'h, C | 1 |
| Deleens, R | 1 |
| Delorme, C | 1 |
| de Montgazon, G | 1 |
| Dixneuf, V | 1 |
| Dy, L | 1 |
| Gaillard, J | 1 |
| Gov, C | 1 |
| Kieffer, X | 1 |
| Lanteri-Minet, M | 1 |
| Le Borgne, JM | 1 |
| Le Caër, F | 1 |
| Maamar, F | 1 |
| Maindet, C | 1 |
| Marcaillou, F | 1 |
| Plantevin, F | 1 |
| Pluchon, YM | 1 |
| Rioult, B | 1 |
| Rostaing, S | 1 |
| Salvat, E | 1 |
| Sep Hieng, V | 1 |
| Sorel, M | 1 |
| Vergne-Salle, P | 1 |
| Morel, V | 2 |
| de Chazeron, I | 1 |
| Pickering, G | 5 |
| Subramanian, S | 1 |
| Haroutounian, S | 2 |
| Palanca, BJA | 1 |
| Lenze, EJ | 1 |
| Quirk, K | 1 |
| Smith, MA | 1 |
| Nobrega, R | 1 |
| Carullo, V | 1 |
| Thein, SL | 1 |
| Quezado, ZMN | 1 |
| Ru, Q | 2 |
| Lu, Y | 2 |
| Saifullah, AB | 2 |
| Blanco, FA | 2 |
| Yao, C | 2 |
| Cata, JP | 2 |
| Li, DP | 2 |
| Tolias, KF | 2 |
| Li, L | 2 |
| Mangnus, TJP | 2 |
| Dirckx, M | 2 |
| Bharwani, KD | 2 |
| Baart, SJ | 1 |
| Siepman, TAM | 1 |
| Redekop, K | 1 |
| Dik, WA | 1 |
| de Vos, CC | 1 |
| Huygen, FJPM | 2 |
| Ertem, FU | 1 |
| Eubanks, J | 1 |
| Saul, M | 1 |
| Kang, CR | 1 |
| Emerick, T | 1 |
| Yadav, D | 1 |
| Cohen, SP | 5 |
| Khunsriraksakul, C | 1 |
| Cohen, SJ | 1 |
| Moon, JY | 2 |
| Sun, W | 1 |
| Zhou, Y | 1 |
| Wang, J | 3 |
| Fu, Y | 1 |
| Fan, J | 1 |
| Cui, Y | 1 |
| Wu, Y | 1 |
| Wang, L | 1 |
| Yu, Y | 2 |
| Han, R | 1 |
| Lambert, C | 2 |
| Pereira, B | 2 |
| Jin, L | 1 |
| Liang, Y | 1 |
| Miao, P | 1 |
| Huang, Y | 1 |
| Xu, L | 1 |
| Wang, H | 1 |
| Wang, C | 1 |
| Huang, J | 1 |
| Guo, K | 1 |
| McDonald, WM | 1 |
| Wilkinson, MM | 1 |
| Jain, A | 1 |
| Bloomfield, A | 1 |
| Chan, N | 1 |
| Fryml, L | 1 |
| Horace, R | 1 |
| Pyati, S | 1 |
| Ma, X | 1 |
| Yan, J | 1 |
| Jiang, H | 1 |
| Ripsman, D | 1 |
| Grinshpun, G | 1 |
| Striebel, J | 1 |
| Ruppen, W | 2 |
| Schneider, T | 1 |
| Motoyama, Y | 1 |
| Oshiro, Y | 1 |
| Takao, Y | 1 |
| Sato, H | 1 |
| Obata, N | 1 |
| Izuta, S | 1 |
| Mizobuchi, S | 1 |
| Kan, S | 1 |
| Shteamer, JW | 1 |
| Callaway, MA | 1 |
| Patel, P | 1 |
| Singh, V | 1 |
| Banki, L | 1 |
| Büki, A | 1 |
| Horvath, G | 1 |
| Kekesi, G | 1 |
| Kis, G | 1 |
| Somogyvári, F | 1 |
| Jancsó, G | 1 |
| Vécsei, L | 1 |
| Varga, E | 1 |
| Tuboly, G | 1 |
| Kamp, J | 1 |
| Van Velzen, M | 1 |
| Olofsen, E | 2 |
| Boon, M | 1 |
| Dahan, A | 5 |
| Niesters, M | 4 |
| Yang, Y | 1 |
| Maher, DP | 2 |
| Kang, C | 1 |
| Cho, AR | 1 |
| Kim, KH | 1 |
| Lee, EA | 1 |
| Lee, HJ | 1 |
| Kwon, JY | 1 |
| Kim, H | 1 |
| Kim, E | 1 |
| Baik, JS | 1 |
| Kim, C | 1 |
| Short, B | 1 |
| Dong, V | 1 |
| Gálvez, V | 1 |
| Vulovic, V | 1 |
| Martin, D | 1 |
| Bayes, AJ | 1 |
| Zarate, CA | 1 |
| Murrough, JW | 1 |
| McLoughlin, DM | 1 |
| Riva-Posse, P | 1 |
| Schoevers, R | 1 |
| Fraguas, R | 1 |
| Glue, P | 1 |
| Fam, J | 1 |
| McShane, R | 1 |
| Loo, CK | 1 |
| Humo, M | 1 |
| Ayazgök, B | 1 |
| Becker, LJ | 1 |
| Waltisperger, E | 1 |
| Rantamäki, T | 1 |
| Yalcin, I | 1 |
| Pushparaj, H | 1 |
| Bhatia, A | 3 |
| Kirkpatrick, AF | 1 |
| Saghafi, A | 1 |
| Yang, K | 1 |
| Qiu, P | 1 |
| Alexander, J | 1 |
| Bavry, E | 1 |
| Schwartzman, R | 1 |
| Clark, JD | 1 |
| Friesner, ID | 1 |
| Martinez, E | 2 |
| Zhou, H | 2 |
| Gould, JD | 1 |
| Li, A | 1 |
| Chen, ZS | 1 |
| Zhang, Q | 2 |
| Bi, Y | 1 |
| Ye, Y | 1 |
| Zhu, Y | 1 |
| Ma, J | 1 |
| Zhang, X | 1 |
| Liu, B | 1 |
| Vujović, KS | 1 |
| Vučković, S | 1 |
| Stojanović, R | 1 |
| Divac, N | 1 |
| Medić, B | 1 |
| Vujović, A | 1 |
| Srebro, D | 1 |
| Prostran, M | 1 |
| Ikomey, GM | 1 |
| Mbakam, CH | 1 |
| Assoumou, MCO | 1 |
| Brandon, JG | 1 |
| Mesembe, M | 1 |
| Mbamyah, EL | 1 |
| Murphy, E | 1 |
| Tagny, CT | 1 |
| Fernandes, M | 1 |
| Schelotto, M | 1 |
| Doldi, PM | 1 |
| Milani, G | 1 |
| Ariza Manzano, AA | 1 |
| Perera Valdivia, D | 1 |
| Winter Matos, AM | 1 |
| Hamdy Abdelrahim, Y | 1 |
| Hamad Bek, SA | 1 |
| Benitez, BK | 1 |
| Romanelli Tavares, VL | 1 |
| Basendwah, AM | 1 |
| Albuquerque Sousa, LH | 1 |
| Xavier, NF | 1 |
| Zertuche Maldonado, T | 1 |
| Toyomi de Oliveira, S | 1 |
| Chaker, M | 1 |
| Menon Miyake, M | 1 |
| Uygur Kucukseymen, E | 1 |
| Waqar, K | 1 |
| Alkhozondar, OMJ | 1 |
| Bernardo da Silva, R | 1 |
| Droppelmann, G | 1 |
| Vaz de Macedo, A | 1 |
| Nakamura, R | 1 |
| Fregni, F | 1 |
| Maudlin, B | 1 |
| Gibson, SB | 2 |
| Aggarwal, A | 2 |
| Corriger, A | 1 |
| Stronks, DL | 1 |
| Rigo, FK | 2 |
| Trevisan, G | 1 |
| Godoy, MC | 1 |
| Rossato, MF | 2 |
| Dalmolin, GD | 2 |
| Silva, MA | 1 |
| Menezes, MS | 1 |
| Caumo, W | 1 |
| Ferreira, J | 2 |
| Glinn, MA | 1 |
| Lickteig, AJ | 1 |
| Weber, L | 1 |
| Recer, S | 1 |
| Salske, M | 1 |
| Harvey, A | 1 |
| Rappold, B | 1 |
| Stensland, J | 1 |
| Bell, P | 1 |
| Peyton, PJ | 1 |
| Wu, C | 1 |
| Jacobson, T | 1 |
| Hogg, M | 1 |
| Zia, F | 1 |
| Leslie, K | 1 |
| Zhang, Y | 1 |
| Ahmed, S | 1 |
| Doshi, T | 1 |
| Malarick, C | 1 |
| Stabach, K | 1 |
| Mao, J | 1 |
| Chen, L | 1 |
| Baldwin, M | 1 |
| Boilini, H | 1 |
| Lamvu, G | 1 |
| Bigman, D | 1 |
| Kunaparaju, S | 1 |
| Bobrin, B | 1 |
| Michelet, D | 1 |
| Brasher, C | 1 |
| Horlin, AL | 1 |
| Bellon, M | 1 |
| Julien-Marsollier, F | 1 |
| Vacher, T | 1 |
| Pontone, S | 1 |
| Dahmani, S | 1 |
| Nielsen, RV | 2 |
| Humble, SR | 1 |
| Varela, N | 1 |
| Jayaweera, A | 1 |
| Bhaskar, A | 1 |
| Klaess, CC | 1 |
| Jungquist, CR | 1 |
| Crumb, MW | 1 |
| Bryant, C | 1 |
| Atkinson, TJ | 1 |
| Eldufani, J | 1 |
| Nekoui, A | 1 |
| Blaise, G | 1 |
| Gupta, A | 1 |
| First, L | 1 |
| Swain, CA | 1 |
| Buvanendran, A | 1 |
| Schwenk, ES | 1 |
| Wasan, AD | 2 |
| Hurley, RW | 1 |
| Viscusi, ER | 1 |
| Narouze, S | 1 |
| Davis, FN | 1 |
| Ritchie, EC | 1 |
| Lubenow, TR | 1 |
| Hooten, WM | 1 |
| Klatt, E | 1 |
| Zumbrunn, T | 1 |
| Bandschapp, O | 1 |
| Girard, T | 1 |
| Micallef, J | 1 |
| Anaya, AMC | 1 |
| Choi, JK | 1 |
| Lee, CS | 1 |
| Oh, E | 1 |
| Kim, Y | 1 |
| Lee, PB | 1 |
| Kim, YC | 1 |
| Dale, J | 1 |
| Hu, S | 1 |
| Zhang, E | 1 |
| Liu, K | 1 |
| Huang, D | 1 |
| Yang, G | 1 |
| Chen, Z | 1 |
| McCaffrey, N | 1 |
| Flint, T | 1 |
| Kaambwa, B | 1 |
| Fazekas, B | 1 |
| Rowett, D | 1 |
| Currow, DC | 3 |
| Hardy, J | 1 |
| Agar, MR | 1 |
| Quinn, S | 1 |
| Eckermann, S | 1 |
| Anghelescu, DL | 1 |
| Tesney, JM | 1 |
| Davison, SN | 1 |
| Lumanauw, DD | 1 |
| Youn, S | 1 |
| Horeczko, T | 1 |
| Yadav, K | 1 |
| Tanen, DA | 1 |
| Jaksch, W | 1 |
| Likar, R | 1 |
| Aigner, M | 1 |
| Orhurhu, V | 1 |
| Orhurhu, MS | 1 |
| Anwar, S | 1 |
| Cooper, J | 1 |
| Rahman, J | 1 |
| Sharma, C | 1 |
| Langford, R | 1 |
| Bredlau, AL | 1 |
| McDermott, MP | 1 |
| Adams, HR | 1 |
| Dworkin, RH | 1 |
| Venuto, C | 1 |
| Fisher, SG | 1 |
| Dolan, JG | 1 |
| Korones, DN | 1 |
| Martini, C | 1 |
| Landau, R | 1 |
| Bollag, L | 1 |
| Ortner, C | 1 |
| de Godoy, MC | 1 |
| de Menezes, MS | 1 |
| Alvarez, MA | 1 |
| Hernandes, JJ | 1 |
| Moreno, LA | 1 |
| Sinche, M | 1 |
| Jennings, CA | 1 |
| Bobb, BT | 1 |
| Noreika, DM | 1 |
| Coyne, PJ | 1 |
| Pickering, AE | 1 |
| McCabe, CS | 1 |
| Barreveld, AM | 1 |
| Correll, DJ | 1 |
| Liu, X | 1 |
| Max, B | 1 |
| McGowan, JA | 1 |
| Shovel, L | 1 |
| Nedeljkovic, SS | 1 |
| Chaparro, LE | 1 |
| Smith, SA | 1 |
| Moore, RA | 1 |
| Wiffen, PJ | 1 |
| Gilron, I | 1 |
| Chung, SD | 1 |
| Wang, CC | 1 |
| Kuo, HC | 1 |
| Aveline, C | 1 |
| Roux, AL | 1 |
| Hetet, HL | 1 |
| Gautier, JF | 1 |
| Vautier, P | 1 |
| Cognet, F | 1 |
| Bonnet, F | 1 |
| Tena, B | 1 |
| Gomar, C | 1 |
| Rios, J | 1 |
| Vaid, P | 1 |
| McCartney, CJ | 1 |
| Nelligan, K | 1 |
| Hardy, JR | 2 |
| Spruyt, O | 1 |
| Quinn, SJ | 1 |
| Devilee, LR | 1 |
| Hu, J | 1 |
| Liao, Q | 1 |
| Zhang, F | 1 |
| Tong, J | 1 |
| Ouyang, W | 1 |
| Schreiber, JA | 1 |
| McNicol, ED | 1 |
| Schumann, R | 1 |
| Marchetti, F | 1 |
| Coutaux, A | 1 |
| Bellanger, A | 1 |
| Magneux, C | 1 |
| Bourgeois, P | 1 |
| Mion, G | 1 |
| van Hecke, O | 1 |
| Guthrie, B | 1 |
| Li, Y | 1 |
| Jackson, KA | 1 |
| Slon, B | 1 |
| Franco, M | 1 |
| William, L | 1 |
| Poon, P | 1 |
| Coller, JK | 1 |
| Hutchinson, MR | 1 |
| Somogyi, AA | 1 |
| Fanta, S | 1 |
| Kinnunen, M | 1 |
| Backman, JT | 1 |
| Kalso, E | 1 |
| Juel, J | 1 |
| Olesen, SS | 1 |
| Olesen, AE | 1 |
| Poulsen, JL | 1 |
| Wilder-Smith, O | 1 |
| Madzak, A | 1 |
| Frøkjær, JB | 1 |
| Drewes, AM | 1 |
| Tauben, D | 1 |
| Richebé, P | 1 |
| Julien, M | 1 |
| Brulotte, V | 1 |
| Martinez, V | 1 |
| Derivaux, B | 1 |
| Beloeil, H | 1 |
| Reddi, D | 1 |
| Sheehy, KA | 1 |
| Muller, EA | 1 |
| Lippold, C | 1 |
| Nouraie, M | 1 |
| Finkel, JC | 1 |
| Quezado, ZM | 1 |
| Schoevers, RA | 1 |
| Chaves, TV | 1 |
| Balukova, SM | 1 |
| aan het Rot, M | 1 |
| Kortekaas, R | 1 |
| Zekry, O | 1 |
| Motov, SM | 1 |
| Nelson, LS | 1 |
| Badiola, IJ | 1 |
| Jafarinia, M | 1 |
| Afarideh, M | 1 |
| Tafakhori, A | 1 |
| Arbabi, M | 1 |
| Ghajar, A | 1 |
| Noorbala, AA | 1 |
| Saravi, MA | 1 |
| Agah, E | 1 |
| Akhondzadeh, S | 1 |
| Ozcan, J | 1 |
| Nicholls, K | 1 |
| Jones, K | 1 |
| Fomsgaard, JS | 1 |
| Siegel, H | 1 |
| Martusevicius, R | 1 |
| Nikolajsen, L | 1 |
| Dahl, JB | 1 |
| Mathiesen, O | 1 |
| Carter, BS | 1 |
| Brunkhorst, J | 1 |
| Truin, M | 1 |
| Janssen, SP | 1 |
| van Kleef, M | 1 |
| Joosten, EA | 1 |
| Patil, S | 1 |
| Anitescu, M | 1 |
| Bell, RF | 1 |
| Sigtermans, M | 1 |
| Noppers, I | 1 |
| Mooren, R | 1 |
| Bauer, M | 1 |
| Aarts, L | 2 |
| Sarton, E | 2 |
| Quinlan, J | 1 |
| Kalkan, Y | 1 |
| Tomak, Y | 1 |
| Altuner, D | 1 |
| Tumkaya, L | 1 |
| Bostan, H | 1 |
| Yilmaz, A | 1 |
| Unal, D | 1 |
| Kara, A | 1 |
| Turan, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intravenous Infusions of S-KETAMINE in Fibromyalgia Syndromes: an Exploratory Study.[NCT04436250] | 210 participants (Anticipated) | Interventional | 2020-10-10 | Recruiting | |||
| Long-term Pain Modulation by Intravenous Esketamine in Complex Regional Pain Syndrome: a Non-inferiority Study[NCT05212571] | 60 participants (Anticipated) | Interventional | 2022-04-19 | Enrolling by invitation | |||
| (2R,6R)-Hydroxynorketamine a Novel Therapeutic Analgesic for the Treatment of Neuropathic Pain: A Randomized Double Blind Cross-Over Trial.[NCT05864053] | Phase 1/Phase 2 | 25 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| OBSERVATIONAL STUDY OF THE MANAGEMENT OF PATIENTS WITH CHRONIC PAIN[NCT03319238] | 1,000 participants (Anticipated) | Observational | 2016-07-07 | Recruiting | |||
| The Effect and Contribution of a Perioperative Ketamine Infusion in an Established Enhanced Recovery Pathway[NCT04625283] | Phase 4 | 1,544 participants (Anticipated) | Interventional | 2021-04-12 | Enrolling by invitation | ||
| Effect of Ketamine on Opioid-Induced Hyperalgesia[NCT00833755] | 79 participants (Actual) | Interventional | 2008-09-30 | Completed | |||
| Efficacy of Different Dose Esketamine and Dexmedetomidine Combination for Supplemental Analgesia After Scoliosis Correction Surgery: A Randomized, Double-blind Trial[NCT06062550] | Phase 4 | 312 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | ||
| Impact of Different Dose Esketamine and Dexmedetomidine Combination for Supplemental Analgesia on Long-term Outcomes After Scoliosis Correction Surgery: Follow-up of a Randomized Trial[NCT06087510] | Phase 4 | 312 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| Low-dose S-ketamine and Dexmedetomidine in Combination With Opioids for Patient-controlled Analgesia After Scoliosis Correction Surgery: a Randomized, Double-blind, Placebo-controlled Trial[NCT04791059] | Phase 4 | 200 participants (Actual) | Interventional | 2021-04-09 | Completed | ||
| Effect of Mini-dose Esketamine-dexmedetomidine Supplemented Analgesia on Long-term Outcomes Following Scoliosis Correction Surgery: 2-year Follow-up of a Randomized Controlled Trial[NCT05718544] | Phase 4 | 199 participants (Actual) | Interventional | 2023-01-30 | Active, not recruiting | ||
| Ketamine for Refractory Chronic Migraine: a Pilot Study[NCT03896256] | Early Phase 1 | 6 participants (Actual) | Interventional | 2019-03-22 | Completed | ||
| Subdissociative Dose Ketamine for Treatment of Acute Pain in Subjects With Chronic Pain: A Randomized Controlled Trial[NCT02920528] | Phase 3 | 106 participants (Actual) | Interventional | 2017-05-01 | Completed | ||
| A Multi-center Randomized Controlled Trial of Efficacy and Safety of Intravenous Ketamine for Chronic Daily Headaches: The KetHead Study[NCT05306899] | Phase 3 | 56 participants (Anticipated) | Interventional | 2022-06-01 | Recruiting | ||
| Peri-Operative Pregabalin for Reducing opIoid Consumption AfTer Cardiac surgEry: A Randomized Trial[NCT04517110] | Phase 3 | 17 participants (Actual) | Interventional | 2021-04-09 | Terminated (stopped due to The COVID-19 pandemic has reduced recruitment such that the study is no longer feasible) | ||
| A Pilot Study of the Use of Oral Ketamine for Treatment of Vaso-Occlusive Pain in Adolescents and Young Adults[NCT05378555] | Phase 3 | 10 participants (Anticipated) | Interventional | 2023-05-01 | Recruiting | ||
| Oral Ketamine for Control of Chronic Pain in Children[NCT01369680] | Phase 1 | 12 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| Ambulatory Infusions of Lidocaine and Ketamine for Management of Chronic Pain: an Observational Prospective Study[NCT04123652] | Phase 4 | 162 participants (Actual) | Interventional | 2017-11-05 | Completed | ||
| A Safe Ketamine-Based Therapy for Treatment Resistant Depression[NCT01179009] | 20 participants (Actual) | Interventional | 2012-04-30 | Completed | |||
| IN Dexmedetomidine for Procedural Sedation in Pediatric Closed Reductions for Distal Forearm Fractures. Timmons Z MD, Feudale B MD Children Presenting to the ED With Distal Forearm Extremity Fractures Often Require Re-alignment Under Conscious Sedation. T[NCT03466242] | Early Phase 1 | 40 participants (Anticipated) | Interventional | 2018-05-01 | Not yet recruiting | ||
| Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis (AKTSS)[NCT03296345] | Phase 2 | 62 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| Comparing the Effectiveness of Low-dose Ketamine With Morphine to Treat Pain in Patients With Long Bone Fractures[NCT02430818] | 13 participants (Actual) | Interventional | 2015-04-30 | Terminated (stopped due to were not able to enroll patients to a satisfactory level) | |||
| Ketamine Infusion for Acute Sickle Cell crisiS in the Emergency Department[NCT02417298] | 12 participants (Actual) | Interventional | 2015-11-30 | Terminated (stopped due to Feasibility) | |||
| Is The Pre-Emptive Administration Of Ketamine A Significant Adjunction To Intravenous Morphine Analgesia For Controlling Post-Operative Pain? A Randomized, Double Blind, Placebo Controlled Clinical Trial.[NCT03415191] | 75 participants (Actual) | Interventional | 2012-01-05 | Completed | |||
| Opioid-Free Shoulder Arthroplasty[NCT03540030] | Phase 4 | 86 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Efficacy and Side Effects of Intrathecal Morphine in Multimodal Analgesia for Unilateral Total Knee Arthroplasty[NCT03232957] | 131 participants (Actual) | Interventional | 2017-08-01 | Completed | |||
| Effect of Paracetamol and Ibuprofen When Intravenously Given Combination or Alone in Reducing Morphine Requirements After Total Knee Arthroplasty[NCT04414995] | Phase 2/Phase 3 | 36 participants (Actual) | Interventional | 2020-06-05 | Completed | ||
| Persistent Postsurgical Pain (PPSP) Following Cystectomy: A Survey and Sensory Examination[NCT02751346] | 383 participants (Actual) | Observational | 2016-01-31 | Completed | |||
| A Combination Study With Sub-Dissociative Ketamine and Fentanyl to Treat Moderate to Severe Pain in the Emergency Department[NCT03959852] | Phase 4 | 6 participants (Actual) | Interventional | 2019-11-18 | Terminated (stopped due to Residency completed.) | ||
| Analgesic Effects of Low-dose S-ketamine in Patients Undergoing Major Spine Fusion Surgery: A Double-blinded, Randomized Controlled Trial[NCT04964219] | Phase 4 | 164 participants (Anticipated) | Interventional | 2022-02-08 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Using QST, we detected the duration (seconds) of tolerance to supra-threshold heat pain stimulation. In this test, subjects were asked to tolerate, as long as he or she could, heat stimulation preset at 47°C for a maximum of 60 seconds. They were given the computer mouse to stop the test if they reached their limit before 60 seconds. If they stopped the test before the 60 seconds, the time that they stopped it was recorded.~This test was repeated 3 times and an average duration was calculated. The duration could range from a minimum of 0 seconds to a maximum of 60 seconds." (NCT00833755)
Timeframe: Baseline at visit 1, post inufsion at visit 1, and at visit 2 which was 1 week after visit 1
| Intervention | seconds (Mean) |
|---|---|
| Opioid - Ketamine | -5.22 |
| Opioid - Placebos | 13.81 |
| Non-opioid - Ketamine | -1.91 |
| Non-opioid - Placebos | -0.39 |
"We measured the change in pain threshold using Quantitative Sensory Testing (QST). QST refers to a set of quantitative testing of individual responses to mechanical, thermal, and/or electrical stimulation. In this study, pain threshold was the thermal stimulation intensity (in°C) first perceived as painful. To measure this, a contact thermode was attached onto the dorsal surface of the forearm. By pressing a computer mouse button, each subject was able to stop stimulation when they first perceived a painful stimulation from the thermode as the temperature increased 1°C/s.~This test was repeated 3 times and an average temperature was calculated. The temperatures could range from a minimum of 0°C to 53°C." (NCT00833755)
Timeframe: Baseline at visit 1, post inufsion at visit 1, and at visit 2 which was 1 week after visit 1
| Intervention | Degrees Celsius (Mean) |
|---|---|
| Opioid - Ketamine | -0.02 |
| Opioid - Placebos | -0.61 |
| Non-opioid - Ketamine | -0.61 |
| Non-opioid - Placebos | -0.77 |
"Using QST, we measured the change in pain tolerance which was the maximum thermal stimulation intensity (in °C) tolerable. In this test, the subject was instructed to press the computer mouse to stop stimulation when the thermode reached the maximal tolerable temperature.~This test was repeated 3 times and an average temperature was calculated. The temperatures could range from a minimum of 0°C to 53°C." (NCT00833755)
Timeframe: Baseline at visit 1, post inufsion at visit 1, and at visit 2 which was 1 week after visit 1
| Intervention | Degrees Celsius (Mean) |
|---|---|
| Opioid - Ketamine | -0.06 |
| Opioid - Placebo | 0.52 |
| Non-opioid - Ketamine | -0.42 |
| Non-opioid - Placebos | -0.19 |
The primary endpoint was clinically significant pain relief defined a priori as a decrease in the pain VAS of at least 20 mm from baseline, which was arbitrarily chosen as the minimal amount that may be important to this group of patients and was extrapolated from studies of acute pain management in the ED. Using an effect size of 20-mm change in VAS as the marker for a successful outcome and the proportion of successes by group as the analysis point, we performed a power analysis using three groups: 0.5 mg/kg ketamine, 0.25 mg/kg ketamine, and placebo and found that a sample size of 96 subjects would be required to detect a statistically significant difference among groups with a power of 90% (a = 0.05). Expecting a loss of 10% of subjects due to patient withdrawal or incomplete data, 106 subjects were recruited. Only subjects who completed the 60-minute study and had data recorded for each of the time points were included in the analysis. (NCT02920528)
Timeframe: 60 minutes
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 13 |
| Very Low Dose Ketamine | 28 |
| Low Dose Ketamine | 25 |
Subjects will be continuously assessed for complications secondary to the sub-dissociative ketamine (NCT02920528)
Timeframe: 1 hour
| Intervention | recorded adverse events (Number) |
|---|---|
| Placebo | 1 |
| Very Low Dose Ketamine | 14 |
| Low Dose Ketamine | 12 |
Subjects were contacted by phone 24 - 48 hours after the completion of the study infusion. Subjects were asked to score their pain on 10-point numeric rating scale where 0 represented no pain and 10 represented the worst pain they could be having. Pain score was recorded in increments of 1 from 0 - 10. Results were compared between groups using the Mann-Whitney U-test. (NCT02920528)
Timeframe: 24 - 48 hours after study drug infusion
| Intervention | units on a scale (Median) |
|---|---|
| Placebo | 5 |
| Very Low Dose Ketamine | 5 |
| Low Dose Ketamine | 6 |
"Baseline neurocognitive testing will be done before study drug is given. Subjects will be reassessed for any changes in neurocognitive scores at end of dosing (week 2) and at three weeks off study drug (week 14). Significant changes were measured at week 14 compared to baseline. Week 2 was measured to inform future studies.~The neurocognitive scores are standardized scores with a mean of 100; low scores correlate with low neurocognitive function, while high scores correlate with high function. A significant change is defined as greater than or equal to 10% decrease in scores." (NCT01369680)
Timeframe: At 14 weeks
| Intervention | participants (Number) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 0 |
| Ketamine 0.5 mg/kg/Dose | 0 |
| Ketamine 1 mg/kg/Dose | 0 |
| Ketamine 1.5 mg/kg/Dose | 0 |
Pharmacokinetic testing will be done during chronic ketamine administration on subjects consenting to additional testing one week into study drug administration. This is to further describe the activity of ketamine in the blood of children when administered chronically and to enable comparison of any clinical effect or toxicity with steady state levels of ketamine in children. (NCT01369680)
Timeframe: At week 1
| Intervention | ng/mL (Mean) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 37.5 |
| Ketamine 0.5 mg/kg/Dose | 135 |
| Ketamine 1 mg/kg/Dose | 250 |
According to CTCae any dose causing grade 2 or worse toxicity will be an untolerated dose. Tolerability is defined as ability to take the medication for 2 weeks without having a grade 2 or worse toxicity. (NCT01369680)
Timeframe: Up to 2 weeks
| Intervention | participants (Number) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 3 |
| Ketamine 0.5 mg/kg/Dose | 3 |
| Ketamine 1 mg/kg/Dose | 3 |
| Ketamine 1.5 mg/kg/Dose | 1 |
"Subjects will be assessed for clinically significant change in pain scores during and after study drug administration. Significant change in pain scores were determined at week 2, though week 14 scores were collected as well.~Participants with a 2 point (or greater) decrease in pain scores compared to baseline were considered to have responded. The NRS scale was used, the scale ranges from 0-10, with 10 being the most pain." (NCT01369680)
Timeframe: Week 2
| Intervention | participants (Number) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 3 |
| Ketamine 0.5 mg/kg/Dose | 0 |
| Ketamine 1 mg/kg/Dose | 2 |
| Ketamine 1.5 mg/kg/Dose | 0 |
The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item scale that measures the severity of depression, with a higher score indicating a higher level of depression. The range of scores is 0 to 60. (NCT01179009)
Timeframe: 8 weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| Ketamine 100-hour Infusion | -9.0 |
| Ketamine 40-minute Infusion | -6.4 |
Opioid usage for at least one but up to three prior patient visits in the last one year for each patient enrolled in the study was summarized, expressed as morphine equivalents in mg/kg/h, to account for different types of opioids used per patient preference, and then this was compared to the intervention group that received LDK. Percent change in opioid usage (expressed as morphine equivalents in mg/kg/h) is reported). (NCT03296345)
Timeframe: Up to one year prior and after LDK administration on day 1 of the study in the ED
| Intervention | percent change (Mean) |
|---|---|
| Intervention | -15 |
"Percent discharge from the ED for intervention group and for at least one but up to three visits prior to receipt of ketamine in the last one year, were assessed. Participants were assigned a 0 if discharged or 1 if not discharged." (NCT03296345)
Timeframe: Up to one year prior to receipt of ketamine for the historical control arm/group and up to 18 months for the intervention arm/group
| Intervention | percentage of participants (Number) |
|---|---|
| Intervention | 33 |
| Historical Control | 17 |
Patient pain scores at presentation for the enrolled encounters and for at least one but up to three visits prior to receipt of ketamine in the last one year, were assessed. At least one but up to three prior visits were averaged and compared to the intervention visit. Pain was assessed using the faces pain scale which consists of a series of line diagrams of faces with expressions of increasing distress. The score ranges from 0 (no pain) to 10 (the worst pain). (NCT03296345)
Timeframe: Up to one year prior and on presentation to the ED after LDK administration
| Intervention | Score on a scale (Mean) |
|---|---|
| Intervention | 9.23 |
| Historical Control | 9.08 |
Patient pain scores at time of discharge from the ED/admission to the hospital for at least one but up to three visits prior to receipt of ketamine in the last one year, were assessed. At least one but up to three prior visits were averaged and compared to the intervention visit. Pain scores post receipt of ketamine are presented for the intervention group. Pain was assessed using the faces pain scale which consists of a series of line diagrams of faces with expressions of increasing distress. The score ranges from 0 (no pain) to 10 (the worst pain). (NCT03296345)
Timeframe: At time of discharge from the ED/admission to the hospital (up to one year prior and after LDK administration)
| Intervention | Score on a scale (Mean) |
|---|---|
| Intervention | 7.15 |
| Historical Control | 7.26 |
Length of stay (LOS) in minutes in the ED for at least one but up to three visits prior to receipt of ketamine in the last one year, were assessed. (NCT03296345)
Timeframe: Up to one year prior to and after LDK administration on day 1 of the study in the ED
| Intervention | LOS in minutes (Mean) |
|---|---|
| Intervention | 273.5 |
| Historical Control | 217.3 |
Time to 50% pain reduction (pain reported 50% less than baseline) in minutes for at least one but up to three visits prior to receipt of ketamine in the last one year, were assessed as historical controls. Pain was assessed using the faces pain scale which consists of a series of line diagrams of faces with expressions of increasing distress. The score ranges from 0 (no pain) to 10 (the worst pain). (NCT03296345)
Timeframe: Up to one year prior to and after LDK administration on day 1 of the study in the ED
| Intervention | time to 50% pain reduction in minutes (Mean) |
|---|---|
| Intervention | 116.1 |
| Historical Control | 167.3 |
"After receipt of LDK, patients and/or their parents, based on age, filled out a survey based on a Likert scale regarding their agreement (Strongly Disagree to Strongly Agree) with the following statements: Achieved faster pain relief with LDK, Achieved more complete pain relief with LDK, and Desire to receive LDK in a future vaso-occlusive crisis. There is also an area where patients could provide general comments regarding their experience in receiving LDK.~Count of Participants who agree or strongly agree for each question are reported." (NCT03296345)
Timeframe: after LDK administration on day 1 of the study in the ED
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Achieved faster pain relief? | Achieved more complete pain relief? | Desire to receive LDK in the future? | |
| Intervention | 43 | 30 | 49 |
We will monitor for adverse effects and record for changes in vital signs including nausea and vomiting, hypotension, respiratory depression, laryngospasm, and emotional and psychological effects (emergence reactions). (NCT02430818)
Timeframe: 60 minutes
| Intervention | participants (Number) |
|---|---|
| Ketamine | 1 |
| Morphine | 1 |
Study outcomes involve change in participants' pain as measured by a visual analog scale. The scale is a 10 inch line from 0 to 10 inches with 10 being the most pain and 0 being no pain. There are no units on the scale; it is just a straight line from no pain (0) to the worst pain (10). We assessed at o, 15, and 60 minutes but only scored the VAS at 60 minutes. (NCT02430818)
Timeframe: At 0 minutes and 60 minutes
| Intervention | score on a scale (Median) |
|---|---|
| Ketamine | 4 |
| Morphine | 4 |
Patients will be assessed to determine whether the participant would consider using the drug given to them for pain relief in the future. It was measured on a likert scale from 1-5 with 1 being did not like and would not use the drug again to 5 being like and would definitely receive the medication again. There are no units. The numbers below are the total number of patients that completed this answer. This was only asked on patients that received medication as if they did not receive medication the answer would not make sense. The median value is the likert value on a scale of 1-5 with the standard deviation. (NCT02430818)
Timeframe: 60 minutes
| Intervention | units on a scale (Median) |
|---|---|
| Ketamine | 4 |
| Morphine | 4 |
American Shoulder and Elbow Surgeons (ASES) Shoulder Score for pain and function. Range 0-100. Low score = worse shoulder condition. Function, disability, and pain subscores (all ranges 0-50), and are summed for total ASES score. (NCT03540030)
Timeframe: 2 Weeks
| Intervention | units on a scale (Median) |
|---|---|
| Observational | 54.3 |
| Non-Opioid Intervention | 54.2 |
Morphine milli-equivalents In-hospital post-operative. Continuous scale of MME, no defined better/worse. Measured as number and dose of medications taken. For example, if the patient received an opioid, the drug and dose was recorded and converted to MME. A time frame of when to assess opioid use in-hospital post-operative was not used but was a continuous monitor for rescue opioid from in-hospital post-operative through discharge. (NCT03540030)
Timeframe: In-hospital Stay
| Intervention | Morphine milli-equivalents (Median) |
|---|---|
| Observational | 45.0 |
| Non-Opioid Intervention | 19.0 |
Pain at patient discharge or 24-hours, whichever comes first - measured on a 0 (no pain) -10 (worst possible pain) numeric rating scale (NRS). A score of 0(no pain) is preferable to 10(worst possible pain) (NCT03540030)
Timeframe: 24 hours
| Intervention | score on a scale (Median) |
|---|---|
| Observational | 3.0 |
| Non-Opioid Intervention | 2.0 |
Simple Shoulder Test (SST) activity score. Range 0-12. 0 = worse activity score. (NCT03540030)
Timeframe: 2 Months
| Intervention | score on a scale (Median) |
|---|---|
| Observational | 6 |
| Non-Opioid Intervention | 6 |
Simple Shoulder Test (SST) activity score. Range 0-12. 0 = worse activity score. (NCT03540030)
Timeframe: 2 Weeks
| Intervention | score on a scale (Median) |
|---|---|
| Observational | 2.0 |
| Non-Opioid Intervention | 2.0 |
post-operative pain: measured on a 0 (no pain) -10 (worst) numeric rating scale (NRS) at 6hrs, 12hrs, 2 weeks, and 2 months. A score of 0(no pain) is preferable to 10(worst possible pain) (NCT03540030)
Timeframe: 6hrs, 12hrs, 2weeks, 2 months
| Intervention | score on a scale (Median) | |||
|---|---|---|---|---|
| 6 Hrs | 12 hrs | 2 weeks | 2 months | |
| Non-Opioid Intervention | 0.0 | 0 | 0.82 | 0 |
| Observational | 2 | 4 | 1.3 | 0.7 |
rate of constipation (NCT03540030)
Timeframe: 2 Months
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Yes | No | Unknown | |
| Non-Opioid Intervention | 4 | 27 | 4 |
| Observational | 7 | 21 | 2 |
rate of constipation (NCT03540030)
Timeframe: 2 Weeks
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Yes | No | Unknown | |
| Non-Opioid Intervention | 13 | 22 | 0 |
| Observational | 19 | 9 | 2 |
rate of falls (NCT03540030)
Timeframe: 2 Months
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Yes | No | Unknown | |
| Non-Opioid Intervention | 4 | 27 | 4 |
| Observational | 4 | 24 | 2 |
rate of falls (NCT03540030)
Timeframe: 2 Weeks
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Yes | No | Unknown | |
| Non-Opioid Intervention | 5 | 30 | 0 |
| Observational | 1 | 27 | 2 |
rate of nausea (NCT03540030)
Timeframe: 2 Months
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Yes | No | Unknown | |
| Non-Opioid Intervention | 1 | 30 | 0 |
| Observational | 0 | 28 | 2 |
rate of nausea (NCT03540030)
Timeframe: 2 Weeks
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Yes | No | Unknown | |
| Non-Opioid Intervention | 1 | 34 | 0 |
| Observational | 5 | 23 | 2 |
Satisfaction with overall pain using Numeric Pain Rating (NRS) scale. yes, no. No being better than yes. (NCT03540030)
Timeframe: 2 Months
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Yes | No | Unknown | |
| Non-Opioid Intervention | 29 | 2 | 4 |
| Observational | 23 | 5 | 2 |
Satisfaction with overall pain using Numeric Pain Rating (NRS) scale. yes, no. No being better than yes. (NCT03540030)
Timeframe: 2 Weeks
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Yes | No | Unknown | |
| Non-Opioid Intervention | 34 | 1 | 0 |
| Observational | 27 | 1 | 2 |
quality of life using VR-12 subscores. Physical Health (PCS) subscore and Mental Health (MCS) subscore, not summed. Range reported in weighted units. Physical Health subscore: 1 point increase in PCS is associated with 6% lower total health care expenditures, 5% lower pharmacy expenditures, 9% lower rate of hospital inpatient visits, 4% lower rate of medical provider visits, 5% lower rate of hospital outpatient visits. Mental Health sub score a 1 point increase in MCS is associated with 7% lower total health care expenditures, 4% lower pharmacy expenditures, 15% lower rate of hospital inpatient visits, and 4% lower rate of medical provider visits. Both PCS/MCS are score 0-100 with 100 indicating the highest level of health. (NCT03540030)
Timeframe: 2 Months
| Intervention | score on a scale (Median) | |
|---|---|---|
| PCS | MCS | |
| Non-Opioid Intervention | 40.3 | 60.8 |
| Observational | 38.4 | 58.7 |
quality of life using VR-12 subscores. Physical Health (PCS) subscore and Mental Health (MCS) subscore, not summed. Range reported in weighted units. Physical Health subscore: 1 point increase in PCS is associated with 6% lower total health care expenditures, 5% lower pharmacy expenditures, 9% lower rate of hospital inpatient visits, 4% lower rate of medical provider visits, 5% lower rate of hospital outpatient visits. Mental Health sub score a 1 point increase in MCS is associated with 7% lower total health care expenditures, 4% lower pharmacy expenditures, 15% lower rate of hospital inpatient visits, and 4% lower rate of medical provider visits. Both PCS/MCS are score 0-100 with 100 indicating the highest level of health. (NCT03540030)
Timeframe: 2 Weeks
| Intervention | score on a scale (Median) | |
|---|---|---|
| PCS | MCS | |
| Non-Opioid Intervention | 35.0 | 59.1 |
| Observational | 36.7 | 56.3 |
33 reviews available for ketamine and Pain, Chronic
| Article | Year |
|---|---|
Quality of meta-analyses of non-opioid, pharmacological, perioperative interventions for chronic postsurgical pain: a systematic review.
Topics: Adult; Chronic Pain; Gabapentin; Humans; Ketamine; Pain, Postoperative; Pregabalin | 2022 |
Effects of Ketamine on Chronic Postsurgical Pain in Patients Undergoing Surgery: A Systematic Review and Meta-analysis.
Topics: Analgesics, Opioid; Chronic Pain; Humans; Ketamine; Pain, Postoperative; Postoperative Nausea and Vo | 2023 |
Ketamine for Chronic Pain and Mental Health: Regulations, Legalities, and the Growth of Infusion Clinics.
Topics: Analgesics; Anesthetics; Chronic Pain; Humans; Ketamine; Mental Health | 2023 |
Application of Ketamine in Pain Management and the Underlying Mechanism.
Topics: Affect; Analgesia; Chronic Pain; Humans; Ketamine; Pain Management | 2023 |
Pharmacokinetic and pharmacodynamic considerations for NMDA-receptor antagonist ketamine in the treatment of chronic neuropathic pain: an update of the most recent literature.
Topics: Analgesics; Animals; Chronic Pain; Excitatory Amino Acid Antagonists; Humans; Ketamine; Neuralgia | 2019 |
Emerging concepts on the use of ketamine for chronic pain.
Topics: Analgesics; Animals; Chronic Pain; Depression; Disease Models, Animal; Excitatory Amino Acid Antagon | 2020 |
Development of the Ketamine Side Effect Tool (KSET).
Topics: Chronic Pain; Drug-Related Side Effects and Adverse Reactions; Humans; Ketamine; Reproducibility of | 2020 |
The Effect of Ketamine on Acute and Chronic Wound Pain in Patients Undergoing Breast Surgery: A Meta-Analysis and Systematic Review.
Topics: Acute Pain; Analgesics; Analgesics, Opioid; Breast Neoplasms; Bupivacaine; Chronic Pain; Female; Hum | 2021 |
Interactions between Ketamine and Magnesium for the Treatment of Pain: Current State of the Art.
Topics: Analgesics; Animals; Chronic Pain; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy | 2021 |
Ketamine for chronic non-cancer pain: A meta-analysis and trial sequential analysis of randomized controlled trials.
Topics: Chronic Pain; Humans; Ketamine; Pain Management; Randomized Controlled Trials as Topic; Treatment Ou | 2018 |
Adjuvant analgesics for spine surgery.
Topics: Analgesia; Analgesics, Opioid; Chlorzoxazone; Chronic Pain; Dexamethasone; Humans; Intraoperative Pe | 2018 |
Adjuvant analgesics for spine surgery.
Topics: Analgesia; Analgesics, Opioid; Chlorzoxazone; Chronic Pain; Dexamethasone; Humans; Intraoperative Pe | 2018 |
Adjuvant analgesics for spine surgery.
Topics: Analgesia; Analgesics, Opioid; Chlorzoxazone; Chronic Pain; Dexamethasone; Humans; Intraoperative Pe | 2018 |
Adjuvant analgesics for spine surgery.
Topics: Analgesia; Analgesics, Opioid; Chlorzoxazone; Chronic Pain; Dexamethasone; Humans; Intraoperative Pe | 2018 |
Adjuvant analgesics for spine surgery.
Topics: Analgesia; Analgesics, Opioid; Chlorzoxazone; Chronic Pain; Dexamethasone; Humans; Intraoperative Pe | 2018 |
Adjuvant analgesics for spine surgery.
Topics: Analgesia; Analgesics, Opioid; Chlorzoxazone; Chronic Pain; Dexamethasone; Humans; Intraoperative Pe | 2018 |
Adjuvant analgesics for spine surgery.
Topics: Analgesia; Analgesics, Opioid; Chlorzoxazone; Chronic Pain; Dexamethasone; Humans; Intraoperative Pe | 2018 |
Adjuvant analgesics for spine surgery.
Topics: Analgesia; Analgesics, Opioid; Chlorzoxazone; Chronic Pain; Dexamethasone; Humans; Intraoperative Pe | 2018 |
Adjuvant analgesics for spine surgery.
Topics: Analgesia; Analgesics, Opioid; Chlorzoxazone; Chronic Pain; Dexamethasone; Humans; Intraoperative Pe | 2018 |
Adjuvant analgesics for spine surgery.
Topics: Analgesia; Analgesics, Opioid; Chlorzoxazone; Chronic Pain; Dexamethasone; Humans; Intraoperative Pe | 2018 |
Adjuvant analgesics for spine surgery.
Topics: Analgesia; Analgesics, Opioid; Chlorzoxazone; Chronic Pain; Dexamethasone; Humans; Intraoperative Pe | 2018 |
Adjuvant analgesics for spine surgery.
Topics: Analgesia; Analgesics, Opioid; Chlorzoxazone; Chronic Pain; Dexamethasone; Humans; Intraoperative Pe | 2018 |
Adjuvant analgesics for spine surgery.
Topics: Analgesia; Analgesics, Opioid; Chlorzoxazone; Chronic Pain; Dexamethasone; Humans; Intraoperative Pe | 2018 |
Adjuvant analgesics for spine surgery.
Topics: Analgesia; Analgesics, Opioid; Chlorzoxazone; Chronic Pain; Dexamethasone; Humans; Intraoperative Pe | 2018 |
Adjuvant analgesics for spine surgery.
Topics: Analgesia; Analgesics, Opioid; Chlorzoxazone; Chronic Pain; Dexamethasone; Humans; Intraoperative Pe | 2018 |
Adjuvant analgesics for spine surgery.
Topics: Analgesia; Analgesics, Opioid; Chlorzoxazone; Chronic Pain; Dexamethasone; Humans; Intraoperative Pe | 2018 |
Chronic postsurgical pain and cancer: the catch of surviving the unsurvivable.
Topics: Analgesics; Analgesics, Opioid; Cancer Pain; Chronic Pain; Drug Therapy, Combination; Gabapentin; Ge | 2018 |
Emerging Trends in Pain Medication Management: Back to the Future: A Focus on Ketamine.
Topics: Analgesics; Chronic Pain; Humans; Ketamine; Pain; Pain Management | 2018 |
Nonanesthetic Effects of Ketamine: A Review Article.
Topics: Chronic Pain; Cognition; Dementia; Depression; Excitatory Amino Acid Antagonists; Humans; Ketamine | 2018 |
Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.
Topics: Analgesics; Anesthesia, Conduction; Anesthesiologists; Chronic Pain; Consensus; Humans; Infusions, I | 2018 |
Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.
Topics: Analgesics; Anesthesia, Conduction; Anesthesiologists; Chronic Pain; Consensus; Humans; Infusions, I | 2018 |
Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.
Topics: Analgesics; Anesthesia, Conduction; Anesthesiologists; Chronic Pain; Consensus; Humans; Infusions, I | 2018 |
Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.
Topics: Analgesics; Anesthesia, Conduction; Anesthesiologists; Chronic Pain; Consensus; Humans; Infusions, I | 2018 |
Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.
Topics: Analgesics; Anesthesia, Conduction; Anesthesiologists; Chronic Pain; Consensus; Humans; Infusions, I | 2018 |
Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.
Topics: Analgesics; Anesthesia, Conduction; Anesthesiologists; Chronic Pain; Consensus; Humans; Infusions, I | 2018 |
Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.
Topics: Analgesics; Anesthesia, Conduction; Anesthesiologists; Chronic Pain; Consensus; Humans; Infusions, I | 2018 |
Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.
Topics: Analgesics; Anesthesia, Conduction; Anesthesiologists; Chronic Pain; Consensus; Humans; Infusions, I | 2018 |
Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.
Topics: Analgesics; Anesthesia, Conduction; Anesthesiologists; Chronic Pain; Consensus; Humans; Infusions, I | 2018 |
Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.
Topics: Analgesics; Anesthesia, Conduction; Anesthesiologists; Chronic Pain; Consensus; Humans; Infusions, I | 2018 |
Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.
Topics: Analgesics; Anesthesia, Conduction; Anesthesiologists; Chronic Pain; Consensus; Humans; Infusions, I | 2018 |
Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.
Topics: Analgesics; Anesthesia, Conduction; Anesthesiologists; Chronic Pain; Consensus; Humans; Infusions, I | 2018 |
Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.
Topics: Analgesics; Anesthesia, Conduction; Anesthesiologists; Chronic Pain; Consensus; Humans; Infusions, I | 2018 |
Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.
Topics: Analgesics; Anesthesia, Conduction; Anesthesiologists; Chronic Pain; Consensus; Humans; Infusions, I | 2018 |
Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.
Topics: Analgesics; Anesthesia, Conduction; Anesthesiologists; Chronic Pain; Consensus; Humans; Infusions, I | 2018 |
Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.
Topics: Analgesics; Anesthesia, Conduction; Anesthesiologists; Chronic Pain; Consensus; Humans; Infusions, I | 2018 |
Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.
Topics: Analgesics; Anesthesia, Conduction; Anesthesiologists; Chronic Pain; Consensus; Humans; Infusions, I | 2018 |
Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.
Topics: Analgesics; Anesthesia, Conduction; Anesthesiologists; Chronic Pain; Consensus; Humans; Infusions, I | 2018 |
Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.
Topics: Analgesics; Anesthesia, Conduction; Anesthesiologists; Chronic Pain; Consensus; Humans; Infusions, I | 2018 |
Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.
Topics: Analgesics; Anesthesia, Conduction; Anesthesiologists; Chronic Pain; Consensus; Humans; Infusions, I | 2018 |
Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.
Topics: Analgesics; Anesthesia, Conduction; Anesthesiologists; Chronic Pain; Consensus; Humans; Infusions, I | 2018 |
Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.
Topics: Analgesics; Anesthesia, Conduction; Anesthesiologists; Chronic Pain; Consensus; Humans; Infusions, I | 2018 |
Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.
Topics: Analgesics; Anesthesia, Conduction; Anesthesiologists; Chronic Pain; Consensus; Humans; Infusions, I | 2018 |
Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.
Topics: Analgesics; Anesthesia, Conduction; Anesthesiologists; Chronic Pain; Consensus; Humans; Infusions, I | 2018 |
Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.
Topics: Analgesics; Anesthesia, Conduction; Anesthesiologists; Chronic Pain; Consensus; Humans; Infusions, I | 2018 |
Intra- and postoperative intravenous ketamine does not prevent chronic pain: A systematic review and meta-analysis.
Topics: Analgesics; Chronic Pain; Humans; Intraoperative Care; Ketamine; Pain, Postoperative; Postoperative | 2015 |
[Ketamine and chronic pain: A narrative review of its efficacy and its adverse events].
Topics: Analgesics; Chronic Pain; Drug-Related Side Effects and Adverse Reactions; Humans; Ketamine; Pain Ma | 2018 |
Ketamine infusion therapy for chronic pain management in South Korea: A national survey for pain physicians with a narrative review.
Topics: Analgesics; Chronic Pain; Clinical Protocols; Female; Humans; Infusions, Intravenous; Ketamine; Male | 2018 |
[Ketamine in the therapy of chronic pain and depression].
Topics: Analgesics; Chronic Pain; Depression; Humans; Ketamine; Neuralgia | 2019 |
Ketamine Infusions for Chronic Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Topics: Adult; Analgesics; Chronic Pain; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intrav | 2019 |
Ketamine Infusions for Chronic Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Topics: Adult; Analgesics; Chronic Pain; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intrav | 2019 |
Ketamine Infusions for Chronic Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Topics: Adult; Analgesics; Chronic Pain; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intrav | 2019 |
Ketamine Infusions for Chronic Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Topics: Adult; Analgesics; Chronic Pain; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intrav | 2019 |
Ketamine for chronic pain: risks and benefits.
Topics: Analgesics; Anesthetics, Dissociative; Animals; Chronic Pain; Drug Monitoring; Humans; Ketamine; Neu | 2014 |
Ketamine for chronic pain: risks and benefits.
Topics: Analgesics; Anesthetics, Dissociative; Animals; Chronic Pain; Drug Monitoring; Humans; Ketamine; Neu | 2014 |
Ketamine for chronic pain: risks and benefits.
Topics: Analgesics; Anesthetics, Dissociative; Animals; Chronic Pain; Drug Monitoring; Humans; Ketamine; Neu | 2014 |
Ketamine for chronic pain: risks and benefits.
Topics: Analgesics; Anesthetics, Dissociative; Animals; Chronic Pain; Drug Monitoring; Humans; Ketamine; Neu | 2014 |
Ketamine for chronic pain: risks and benefits.
Topics: Analgesics; Anesthetics, Dissociative; Animals; Chronic Pain; Drug Monitoring; Humans; Ketamine; Neu | 2014 |
Ketamine for chronic pain: risks and benefits.
Topics: Analgesics; Anesthetics, Dissociative; Animals; Chronic Pain; Drug Monitoring; Humans; Ketamine; Neu | 2014 |
Ketamine for chronic pain: risks and benefits.
Topics: Analgesics; Anesthetics, Dissociative; Animals; Chronic Pain; Drug Monitoring; Humans; Ketamine; Neu | 2014 |
Ketamine for chronic pain: risks and benefits.
Topics: Analgesics; Anesthetics, Dissociative; Animals; Chronic Pain; Drug Monitoring; Humans; Ketamine; Neu | 2014 |
Ketamine for chronic pain: risks and benefits.
Topics: Analgesics; Anesthetics, Dissociative; Animals; Chronic Pain; Drug Monitoring; Humans; Ketamine; Neu | 2014 |
Chronic pain after childbirth.
Topics: Acute Pain; Adrenergic alpha-Agonists; Adult; Amines; Analgesics; Anesthetics, Dissociative; Cesarea | 2013 |
Pharmacotherapy for the prevention of chronic pain after surgery in adults.
Topics: Adrenal Cortex Hormones; Adult; Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Femal | 2013 |
Postoperative pain management after total knee arthroplasty in elderly patients: treatment options.
Topics: Acetaminophen; Acute Pain; Aged; Analgesics, Opioid; Anesthesia; Anesthesia, Conduction; Anti-Inflam | 2014 |
Postoperative pain management after total knee arthroplasty in elderly patients: treatment options.
Topics: Acetaminophen; Acute Pain; Aged; Analgesics, Opioid; Anesthesia; Anesthesia, Conduction; Anti-Inflam | 2014 |
Postoperative pain management after total knee arthroplasty in elderly patients: treatment options.
Topics: Acetaminophen; Acute Pain; Aged; Analgesics, Opioid; Anesthesia; Anesthesia, Conduction; Anti-Inflam | 2014 |
Postoperative pain management after total knee arthroplasty in elderly patients: treatment options.
Topics: Acetaminophen; Acute Pain; Aged; Analgesics, Opioid; Anesthesia; Anesthesia, Conduction; Anti-Inflam | 2014 |
Postoperative pain management after total knee arthroplasty in elderly patients: treatment options.
Topics: Acetaminophen; Acute Pain; Aged; Analgesics, Opioid; Anesthesia; Anesthesia, Conduction; Anti-Inflam | 2014 |
Postoperative pain management after total knee arthroplasty in elderly patients: treatment options.
Topics: Acetaminophen; Acute Pain; Aged; Analgesics, Opioid; Anesthesia; Anesthesia, Conduction; Anti-Inflam | 2014 |
Postoperative pain management after total knee arthroplasty in elderly patients: treatment options.
Topics: Acetaminophen; Acute Pain; Aged; Analgesics, Opioid; Anesthesia; Anesthesia, Conduction; Anti-Inflam | 2014 |
Postoperative pain management after total knee arthroplasty in elderly patients: treatment options.
Topics: Acetaminophen; Acute Pain; Aged; Analgesics, Opioid; Anesthesia; Anesthesia, Conduction; Anti-Inflam | 2014 |
Postoperative pain management after total knee arthroplasty in elderly patients: treatment options.
Topics: Acetaminophen; Acute Pain; Aged; Analgesics, Opioid; Anesthesia; Anesthesia, Conduction; Anti-Inflam | 2014 |
Understanding the cancer pain experience.
Topics: Acetaminophen; Analgesics; Chronic Pain; Critical Pathways; Fentanyl; Humans; Ketamine; Neoplasms; O | 2014 |
A systematic review and meta-analysis of ketamine for the prevention of persistent post-surgical pain.
Topics: Anesthetics, Dissociative; Chronic Pain; Humans; Ketamine; Pain, Postoperative | 2014 |
Nonopioid medications for pain.
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Antidepressive Agents; Cannabi | 2015 |
Preventing chronic postoperative pain.
Topics: Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; | 2016 |
Oral ketamine for the treatment of pain and treatment-resistant depression†.
Topics: Administration, Oral; Analgesics; Antidepressive Agents; Chronic Pain; Depressive Disorder, Treatmen | 2016 |
Advanced Concepts and Controversies in Emergency Department Pain Management.
Topics: Acetaminophen; Acute Pain; Analgesia, Patient-Controlled; Analgesics, Opioid; Anti-Inflammatory Agen | 2016 |
Can Chronic Pain Be Prevented?
Topics: Acute Pain; Amines; Anesthesia, Conduction; Chronic Pain; Cyclohexanecarboxylic Acids; Epigenesis, G | 2016 |
Neonatal pain management.
Topics: Amines; Analgesics, Opioid; Anti-Anxiety Agents; Barbiturates; Chronic Pain; Cyclohexanecarboxylic A | 2017 |
Ketamine for chronic noncancer pain: concerns regarding toxicity.
Topics: Analgesics; Chemical and Drug Induced Liver Injury; Chronic Pain; Cognition Disorders; Dose-Response | 2012 |
22 trials available for ketamine and Pain, Chronic
| Article | Year |
|---|---|
The place of S-ketamine in fibromyalgia treatment (ESKEFIB): study protocol for a prospective, single-center, double-blind, randomized, parallel-group, dose-escalation controlled trial.
Topics: Chronic Pain; Double-Blind Method; Fibromyalgia; Humans; Ketamine; Prospective Studies; Randomized C | 2021 |
Intermittent versus continuous esketamine infusions for long-term pain modulation in complex regional pain syndrome: protocol of a randomized controlled non-inferiority study (KetCRPS-2).
Topics: Adult; Chronic Pain; Complex Regional Pain Syndromes; Humans; Ketamine; Quality of Life; Randomized | 2023 |
Evaluation of the Effect of New Multimodal Analgesia Regimen for Cardiac Surgery: A Prospective, Randomized Controlled, Single-Center Clinical Study.
Topics: Acetaminophen; Analgesia; Cardiac Surgical Procedures; Chronic Pain; Dexmedetomidine; Gabapentin; Hu | 2023 |
Effects of Intraoperative Low-Dose Ketamine on Persistent Postsurgical Pain after Breast Cancer Surgery: A Prospective, Randomized, Controlled, Double-Blind Study.
Topics: Adult; Analgesics; Breast Neoplasms; Chronic Pain; Double-Blind Method; Female; Humans; Ketamine; Ma | 2020 |
Topics: Analgesics, Opioid; Chronic Pain; Double-Blind Method; Humans; Ketamine; Pain, Intractable; Quality | 2020 |
Management of Neuropathic Chronic Pain with Methadone Combined with Ketamine: A Randomized, Double Blind, Active-Controlled Clinical Trial.
Topics: Adult; Aged; Chronic Pain; Double-Blind Method; Female; Humans; Ketamine; Male; Methadone; Middle Ag | 2017 |
The effect of a perioperative ketamine infusion on the incidence of chronic postsurgical pain-a pilot study.
Topics: Adult; Aged; Chronic Pain; Female; Humans; Incidence; Ketamine; Male; Middle Aged; Pain, Postoperati | 2017 |
Chronic Opioid Therapy Modifies QST Changes After Ketamine Infusion in Chronic Pain Patients.
Topics: Adult; Analgesics, Opioid; Chronic Pain; Excitatory Amino Acid Antagonists; Female; Humans; Ketamine | 2017 |
Subdissociative-dose Ketamine Is Effective for Treating Acute Exacerbations of Chronic Pain.
Topics: Adult; Analgesics; Chronic Pain; Disease Progression; Dose-Response Relationship, Drug; Double-Blind | 2019 |
Prolonged Perioperative Use of Pregabalin and Ketamine to Prevent Persistent Pain after Cardiac Surgery.
Topics: Aged; Analgesics; Cardiac Surgical Procedures; Chronic Pain; Double-Blind Method; Female; Follow-Up | 2019 |
Oral ketamine for children with chronic pain: a pilot phase 1 study.
Topics: Administration, Oral; Adolescent; Analgesics; Child; Chronic Pain; Female; Humans; Ketamine; Male; P | 2013 |
Oral ketamine for children with chronic pain: a pilot phase 1 study.
Topics: Administration, Oral; Adolescent; Analgesics; Child; Chronic Pain; Female; Humans; Ketamine; Male; P | 2013 |
Oral ketamine for children with chronic pain: a pilot phase 1 study.
Topics: Administration, Oral; Adolescent; Analgesics; Child; Chronic Pain; Female; Humans; Ketamine; Male; P | 2013 |
Oral ketamine for children with chronic pain: a pilot phase 1 study.
Topics: Administration, Oral; Adolescent; Analgesics; Child; Chronic Pain; Female; Humans; Ketamine; Male; P | 2013 |
Ketamine decreases postoperative pain scores in patients taking opioids for chronic pain: results of a prospective, randomized, double-blind study.
Topics: Analgesics, Opioid; Anesthetics, Dissociative; Chronic Pain; Double-Blind Method; Drug Therapy, Comb | 2013 |
Pain and recovery after total knee arthroplasty: a 12-month follow-up after a prospective randomized study evaluating Nefopam and Ketamine for early rehabilitation.
Topics: Aged; Analgesics; Arthroplasty, Replacement, Knee; Chronic Pain; Female; Follow-Up Studies; Humans; | 2014 |
Perioperative epidural or intravenous ketamine does not improve the effectiveness of thoracic epidural analgesia for acute and chronic pain after thoracotomy.
Topics: Acute Disease; Administration, Intravenous; Adult; Analgesia, Epidural; Analgesics; Chronic Pain; Co | 2014 |
Chronic postthoracotomy pain and perioperative ketamine infusion.
Topics: Adult; Analgesia, Patient-Controlled; Analgesics; Chronic Pain; Double-Blind Method; Female; Follow- | 2014 |
CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Chronic Pain; Cytochrome P-450 CYP2B6; DNA; Double-Blind | 2015 |
Study protocol for a randomised, double-blinded, placebo-controlled, clinical trial of S-ketamine for pain treatment in patients with chronic pancreatitis (RESET trial).
Topics: Administration, Oral; Analgesics; Analgesics, Opioid; Chronic Pain; Double-Blind Method; Humans; Hyp | 2015 |
Subanesthetic, Subcutaneous Ketamine Infusion Therapy in the Treatment of Chronic Nonmalignant Pain.
Topics: Administration, Sublingual; Analgesics; Analgesics, Opioid; Chronic Pain; Female; Follow-Up Studies; | 2016 |
Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: A double-blind, randomized, controlled trial.
Topics: Administration, Oral; Adult; Antidepressive Agents; Chronic Pain; Depression; Diclofenac; Double-Bli | 2016 |
Intraoperative ketamine reduces immediate postoperative opioid consumption after spinal fusion surgery in chronic pain patients with opioid dependency: a randomized, blinded trial.
Topics: Adult; Aged; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Chronic Pain; Double-Bli | 2017 |
Intraoperative ketamine reduces immediate postoperative opioid consumption after spinal fusion surgery in chronic pain patients with opioid dependency: a randomized, blinded trial.
Topics: Adult; Aged; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Chronic Pain; Double-Bli | 2017 |
Intraoperative ketamine reduces immediate postoperative opioid consumption after spinal fusion surgery in chronic pain patients with opioid dependency: a randomized, blinded trial.
Topics: Adult; Aged; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Chronic Pain; Double-Bli | 2017 |
Intraoperative ketamine reduces immediate postoperative opioid consumption after spinal fusion surgery in chronic pain patients with opioid dependency: a randomized, blinded trial.
Topics: Adult; Aged; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Chronic Pain; Double-Bli | 2017 |
Intraoperative ketamine reduces immediate postoperative opioid consumption after spinal fusion surgery in chronic pain patients with opioid dependency: a randomized, blinded trial.
Topics: Adult; Aged; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Chronic Pain; Double-Bli | 2017 |
Intraoperative ketamine reduces immediate postoperative opioid consumption after spinal fusion surgery in chronic pain patients with opioid dependency: a randomized, blinded trial.
Topics: Adult; Aged; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Chronic Pain; Double-Bli | 2017 |
Intraoperative ketamine reduces immediate postoperative opioid consumption after spinal fusion surgery in chronic pain patients with opioid dependency: a randomized, blinded trial.
Topics: Adult; Aged; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Chronic Pain; Double-Bli | 2017 |
Intraoperative ketamine reduces immediate postoperative opioid consumption after spinal fusion surgery in chronic pain patients with opioid dependency: a randomized, blinded trial.
Topics: Adult; Aged; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Chronic Pain; Double-Bli | 2017 |
Intraoperative ketamine reduces immediate postoperative opioid consumption after spinal fusion surgery in chronic pain patients with opioid dependency: a randomized, blinded trial.
Topics: Adult; Aged; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Chronic Pain; Double-Bli | 2017 |
Intraoperative ketamine reduces immediate postoperative opioid consumption after spinal fusion surgery in chronic pain patients with opioid dependency: a randomized, blinded trial.
Topics: Adult; Aged; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Chronic Pain; Double-Bli | 2017 |
Intraoperative ketamine reduces immediate postoperative opioid consumption after spinal fusion surgery in chronic pain patients with opioid dependency: a randomized, blinded trial.
Topics: Adult; Aged; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Chronic Pain; Double-Bli | 2017 |
Intraoperative ketamine reduces immediate postoperative opioid consumption after spinal fusion surgery in chronic pain patients with opioid dependency: a randomized, blinded trial.
Topics: Adult; Aged; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Chronic Pain; Double-Bli | 2017 |
Intraoperative ketamine reduces immediate postoperative opioid consumption after spinal fusion surgery in chronic pain patients with opioid dependency: a randomized, blinded trial.
Topics: Adult; Aged; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Chronic Pain; Double-Bli | 2017 |
Intraoperative ketamine reduces immediate postoperative opioid consumption after spinal fusion surgery in chronic pain patients with opioid dependency: a randomized, blinded trial.
Topics: Adult; Aged; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Chronic Pain; Double-Bli | 2017 |
Intraoperative ketamine reduces immediate postoperative opioid consumption after spinal fusion surgery in chronic pain patients with opioid dependency: a randomized, blinded trial.
Topics: Adult; Aged; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Chronic Pain; Double-Bli | 2017 |
Intraoperative ketamine reduces immediate postoperative opioid consumption after spinal fusion surgery in chronic pain patients with opioid dependency: a randomized, blinded trial.
Topics: Adult; Aged; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Chronic Pain; Double-Bli | 2017 |
The dose-dependent effect of S(+)-ketamine on cardiac output in healthy volunteers and complex regional pain syndrome type 1 chronic pain patients.
Topics: Adult; Analgesics; Cardiac Output; Chronic Pain; Dose-Response Relationship, Drug; Female; Humans; K | 2012 |
Influence of ketamine and morphine on descending pain modulation in chronic pain patients: a randomized placebo-controlled cross-over proof-of-concept study.
Topics: Analgesics; Chronic Pain; Cross-Over Studies; Double-Blind Method; Female; Humans; Ketamine; Male; M | 2013 |
53 other studies available for ketamine and Pain, Chronic
| Article | Year |
|---|---|
The effects of a multiday (10-14 days) subanesthetic dose IV ketamine infusion in the treatment of refractory chronic pain.
Topics: Analgesics; Analgesics, Opioid; Chronic Pain; Humans; Ketamine; Prospective Studies | 2022 |
Repeated or Continuous Medically Supervised Ketamine Administration Associated with Hepatobiliary Adverse Events: A Retrospective Case Series.
Topics: Chronic Pain; Humans; Ketamine; Retrospective Studies; United States | 2021 |
Increased burst coding in deep layers of the ventral anterior cingulate cortex during neuropathic pain.
Topics: Action Potentials; Anesthesia; Animals; Chronic Pain; Electrophysiology; Gyrus Cinguli; Ketamine; Ma | 2021 |
Ketamine in chronic pain: A Delphi survey.
Topics: Chronic Pain; Complex Regional Pain Syndromes; Humans; Ketamine; Neuralgia; Pain, Intractable | 2022 |
Ketamine as a therapeutic agent for depression and pain: mechanisms and evidence.
Topics: Antidepressive Agents; Chronic Pain; Depression; Humans; Ketamine; Receptors, N-Methyl-D-Aspartate | 2022 |
Risk Factors for the Development of Neuropsychiatric Adverse Effects in Ketamine-Treated Pain.
Topics: Analgesics; Analgesics, Opioid; Benzodiazepines; Chronic Pain; Cohort Studies; Humans; Ketamine; Pai | 2022 |
Subanesthetic ketamine: the way forward for pain management in sickle cell disease patients?
Topics: Acute Pain; Analgesics, Non-Narcotic; Analgesics, Opioid; Anemia, Sickle Cell; Chronic Pain; Humans; | 2022 |
TIAM1-mediated synaptic plasticity underlies comorbid depression-like and ketamine antidepressant-like actions in chronic pain.
Topics: Animals; Antidepressive Agents; Chronic Pain; Depression; Ketamine; Mice; Neuronal Plasticity; T-Lym | 2022 |
TIAM1-mediated synaptic plasticity underlies comorbid depression-like and ketamine antidepressant-like actions in chronic pain.
Topics: Animals; Antidepressive Agents; Chronic Pain; Depression; Ketamine; Mice; Neuronal Plasticity; T-Lym | 2022 |
TIAM1-mediated synaptic plasticity underlies comorbid depression-like and ketamine antidepressant-like actions in chronic pain.
Topics: Animals; Antidepressive Agents; Chronic Pain; Depression; Ketamine; Mice; Neuronal Plasticity; T-Lym | 2022 |
TIAM1-mediated synaptic plasticity underlies comorbid depression-like and ketamine antidepressant-like actions in chronic pain.
Topics: Animals; Antidepressive Agents; Chronic Pain; Depression; Ketamine; Mice; Neuronal Plasticity; T-Lym | 2022 |
Ketamine infusion for pain management in hospitalized patients with Chronic Pancreatitis: A case series.
Topics: Analgesics; Chronic Pain; Humans; Infusions, Intravenous; Ketamine; Pain; Pain Management; Pancreati | 2023 |
Ketamine dose reporting and dose responsiveness for chronic pain.
Topics: Analgesics; Anesthetics, Dissociative; Chronic Pain; Humans; Ketamine | 2023 |
Assessment of Initial Depressive State and Pain Relief With Ketamine in Patients With Chronic Refractory Pain.
Topics: Chronic Pain; Cohort Studies; Female; Humans; Ketamine; Male; Middle Aged; Pain, Intractable; Prospe | 2023 |
The use of ketamine infusion to dramatically reduce opioid requirements in a patient whose high-dose intrathecal opioid pump was inadvertently cut during surgery.
Topics: Analgesics, Opioid; Chronic Pain; Humans; Hyperalgesia; Infusions, Intravenous; Ketamine; Morphine | 2023 |
Therapeutic effects of 7- to 14-day subanesthetic ketamine infusions for chronic pain on standardized psychiatric measures.
Topics: Chronic Pain; Humans; Infusions, Intravenous; Ketamine; Pain Measurement; Pain, Intractable | 2023 |
Chronic Pain Syndromes: Complex Regional Pain Syndrome.
Topics: Chronic Pain; Complex Regional Pain Syndromes; Gabapentin; Humans; Ketamine; Physical Therapy Modali | 2023 |
Simultaneous application of lidocaine and ketamine during ambulatory infusion therapy: a retrospective analysis.
Topics: Chronic Pain; Humans; Infusions, Intravenous; Ketamine; Lidocaine; Retrospective Studies; Treatment | 2023 |
[Ketamine in chronic pain].
Topics: Analgesics; Chronic Pain; Humans; Ketamine; Pain Management | 2023 |
Resting-state brain functional connectivity in patients with chronic pain who responded to subanesthetic-dose ketamine.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Brain; Brain Mapping; Chronic Pain; Connectome; Female; | 2019 |
How effective is ketamine in the management of chronic neuropathic pain?
Topics: Analgesics; Chronic Pain; Excitatory Amino Acid Antagonists; Humans; Ketamine; Neuralgia; Pain Manag | 2019 |
Distinct changes in chronic pain sensitivity and oxytocin receptor expression in a new rat model (Wisket) of schizophrenia.
Topics: Analgesics, Opioid; Animals; Ankle Joint; Brain; Brain Stem; Chronic Pain; Diencephalon; Disease Mod | 2020 |
Ketamine induces rapid and sustained antidepressant-like effects in chronic pain induced depression: Role of MAPK signaling pathway.
Topics: Animals; Antidepressive Agents; Chronic Pain; Depression; Ketamine; Male; MAP Kinase Signaling Syste | 2020 |
Behavioural disturbance after intravenous ketamine infusion for treatment of refractory chronic pain.
Topics: Analgesics; Chronic Pain; Humans; Infusions, Intravenous; Ketamine; Pain, Intractable | 2020 |
Optimizing the Treatment of CRPS With Ketamine.
Topics: Chronic Pain; Complex Regional Pain Syndromes; Humans; Ketamine; Pain Measurement; Pain Threshold | 2020 |
Ketamine for Chronic Pain: Old Drug New Trick?
Topics: Chronic Pain; Cross-Over Studies; Double-Blind Method; Humans; Ketamine; Magnesium; Neuralgia | 2020 |
Ketamine normalizes high-gamma power in the anterior cingulate cortex in a rat chronic pain model.
Topics: Action Potentials; Animals; Chronic Pain; Disease Models, Animal; Freund's Adjuvant; Gamma Rhythm; G | 2020 |
Long-term safety and efficacy of sublingual ketamine troches/lozenges in chronic non-malignant pain management.
Topics: Analgesics; Analgesics, Opioid; Chronic Disease; Chronic Pain; Humans; Ketamine; Pain Management; Qu | 2022 |
Ketamine for refractory chronic pain: a 1-year follow-up study.
Topics: Chronic Pain; Fibromyalgia; Follow-Up Studies; Humans; Ketamine; Neuralgia; Prospective Studies; Qua | 2022 |
Ketamine therapy for chronic pain in The Netherlands: a nationwide survey.
Topics: Analgesics; Chronic Pain; Complex Regional Pain Syndromes; Humans; Ketamine; Netherlands | 2022 |
Urinary Concentrations of Topically Administered Pain Medications.
Topics: Administration, Oral; Administration, Topical; Amines; Amitriptyline; Analgesics; Chronic Pain; Cycl | 2017 |
Chronic Pain and Suicide: Is There a Role for Ketamine?
Topics: Analgesics; Chronic Pain; Humans; Ketamine; Suicide; United States | 2017 |
Use of ketamine for acute suicidal ideation in a patient with chronic pain on prescribed cannabinoids.
Topics: Adult; Bipolar Disorder; Cannabinoids; Chronic Pain; Humans; Injections, Intramuscular; Ketamine; Ma | 2017 |
Current Ketamine Practice: Results of the 2016 American Society of Pain Management Nursing Survey on Ketamine.
Topics: Analgesics; Chronic Pain; Drug Administration Schedule; Humans; Ketamine; Practice Patterns, Nurses' | 2018 |
Successful Improvement of Pain Symptomatology in a Suspected Case of Cramp-Fasciculation Syndrome via Interventional Pain Treatment.
Topics: Adult; Analgesics; Chronic Pain; Female; Humans; Ketamine; Nerve Block; Neuromuscular Diseases; Trea | 2018 |
Ketamine reduces aversion in rodent pain models by suppressing hyperactivity of the anterior cingulate cortex.
Topics: Adjuvants, Immunologic; Animals; Avoidance Learning; Behavior, Animal; Chronic Pain; Disease Models, | 2018 |
Economic evaluation of the randomised, double-blind, placebo-controlled study of subcutaneous ketamine in the management of chronic cancer pain.
Topics: Administration, Cutaneous; Adult; Aged; Australia; Cancer Pain; Chronic Pain; Double-Blind Method; F | 2019 |
Neuropathic Pain in Pediatric Oncology: A Clinical Decision Algorithm.
Topics: Adult; Algorithms; Analgesics; Child; Chronic Pain; Clinical Decision-Making; Humans; Ketamine; Medi | 2019 |
Clinical Pharmacology Considerations in Pain Management in Patients with Advanced Kidney Failure.
Topics: Acetaminophen; Acute Pain; Analgesics, Non-Narcotic; Analgesics, Opioid; Carbamazepine; Chronic Pain | 2019 |
Management of chronic neuropathic pain of different causes with the combination of oral methadone along with ketamine: A report of 18 cases.
Topics: Administration, Oral; Adult; Analgesics, Opioid; Chronic Pain; Drug Combinations; Female; Humans; Ke | 2013 |
Oral ketamine for sickle cell crisis pain refractory to opioids.
Topics: Activities of Daily Living; Acute Pain; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; | 2013 |
Oral ketamine for sickle cell crisis pain refractory to opioids.
Topics: Activities of Daily Living; Acute Pain; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; | 2013 |
Oral ketamine for sickle cell crisis pain refractory to opioids.
Topics: Activities of Daily Living; Acute Pain; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; | 2013 |
Oral ketamine for sickle cell crisis pain refractory to opioids.
Topics: Activities of Daily Living; Acute Pain; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; | 2013 |
Oral ketamine for sickle cell crisis pain refractory to opioids.
Topics: Activities of Daily Living; Acute Pain; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; | 2013 |
Oral ketamine for sickle cell crisis pain refractory to opioids.
Topics: Activities of Daily Living; Acute Pain; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; | 2013 |
Oral ketamine for sickle cell crisis pain refractory to opioids.
Topics: Activities of Daily Living; Acute Pain; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; | 2013 |
Oral ketamine for sickle cell crisis pain refractory to opioids.
Topics: Activities of Daily Living; Acute Pain; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; | 2013 |
Oral ketamine for sickle cell crisis pain refractory to opioids.
Topics: Activities of Daily Living; Acute Pain; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; | 2013 |
Prolonged ketamine infusion as a therapy for complex regional pain syndrome: synergism with antagonism?
Topics: Analgesics; Animals; Chronic Pain; Humans; Ketamine | 2014 |
Augmentation enterocystoplasty is effective in relieving refractory ketamine-related bladder pain.
Topics: Adult; Anastomosis, Surgical; Chronic Pain; Cystitis; Female; Humans; Ileum; Ketamine; Male; Pilot P | 2014 |
Ketamine for acute-on-chronic pain.
Topics: Acute Pain; Analgesics; Chronic Pain; Humans; Infusions, Intravenous; Ketamine; Nursing Staff, Hospi | 2013 |
Implementing practice change in chronic cancer pain management: clinician response to a phase III study of ketamine.
Topics: Adult; Aged; Attitude of Health Personnel; Chronic Pain; Clinical Trials, Phase III as Topic; Diffus | 2014 |
Efficacy and safety of oral ketamine for the relief of intractable chronic pain: A retrospective 5-year study of 51 patients.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Analgesics, Opioid; Anesthetics, Dis | 2015 |
Oral ketamine analgesia in chronic pain and problematic rise in blood pressure.
Topics: Aged; Analgesics; Chronic Pain; Female; Humans; Hypertension; Ketamine; Low Back Pain | 2014 |
Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing.
Topics: Administration, Oral; Adult; Analgesics; Chronic Pain; Healthy Volunteers; Humans; Infusions, Intrav | 2015 |
Potential strategies for preventing chronic postoperative pain: a practical approach: Continuing Professional Development.
Topics: Analgesics, Opioid; Anesthesia, Conduction; Anesthesia, Epidural; Anesthetics, Local; Chronic Pain; | 2015 |
Ketamine for pain management in France, an observational survey.
Topics: Acute Pain; Aged; Anesthetics, Dissociative; Chronic Pain; Female; France; Health Care Surveys; Huma | 2015 |
Subanesthetic ketamine infusions for the treatment of children and adolescents with chronic pain: a longitudinal study.
Topics: Adolescent; Ambulatory Care; Anesthesia, Intravenous; Anesthetics, Dissociative; Child; Chronic Pain | 2015 |
Immunoglobulin E-Mediated Hypersensitivity Reaction to Ketamine.
Topics: Adult; Analgesics; Chronic Pain; Drug Eruptions; Female; Humans; Immunoglobulin E; Ketamine; Pelvic | 2016 |
Successful pain relief in non-responders to spinal cord stimulation: the combined use of ketamine and spinal cord stimulation.
Topics: Analgesics; Animals; Chronic Pain; Combined Modality Therapy; Disease Models, Animal; Electric Stimu | 2011 |
Efficacy of outpatient ketamine infusions in refractory chronic pain syndromes: a 5-year retrospective analysis.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Analgesics; Chronic Pain; Female; Humans; Infusions, Intra | 2012 |
The use of a subanesthetic infusion of intravenous ketamine to allow withdrawal of medically prescribed opioids in people with chronic pain, opioid tolerance and hyperalgesia: outcome at 6 months.
Topics: Analgesics; Analgesics, Opioid; Chronic Pain; Drug Tolerance; Humans; Infusions, Intravenous; Ketami | 2012 |
Hepatic effects of ketamine administration for 2 weeks in rats.
Topics: Analgesics; Anesthetics, Dissociative; Animals; Apoptosis; Calcineurin; Calcineurin Inhibitors; Chem | 2014 |